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Abstract 
The burden of wounds and musculoskeletal (MSK) disorders are rising, primarily due to higher 
life expectancy and the growing epidemic of associated chronic diseases. This has made 
identifying technologies that can improve patient outcomes at the lowest cost possible an 
increasingly important pursuit. The aim of this thesis was to evaluate the clinical and economic 
evidence used to inform coverage and reimbursement decisions of medical devices using 
examples from wound care and MSK disorders. This thesis presents and offers a critique of 8 of 
my publications, which either updated, and or contributed to new knowledge in the field. The 
clinical effectiveness of wound and MSK disorders was explored via systematic literature reviews, 
meta-analysis, and indirect treatment comparison. The clinical evidence was then used to inform 
the cost-effectiveness analysis of these interventions in these patient populations.  
The result of the analyses assessed for this thesis demonstrate; that for burn wound care, 
ACTICOAT was the most cost-effective compared with other silver dressings, whereas the use of 
PICO negative pressure wound therapy following surgical incision was cost-saving from a payer’s 
perspective compared with standard care. Lastly, in MSK disorders, the use of twin-screw intra-
medullary nail InterTAN was found to be cost-saving from a payer’s perspective compared with 
single-screw nails in patients with unstable trochanteric fractures. Using examples of wound and 
MSK disorders, the thesis demonstrates that when clinical and cost-evidence are utilised, 
clinicians and payers are able to make decisions that optimise patients’ outcomes as well as their 
budgetary spend. This was illustrated in the United Kingdom’s National Health Service, where 
PICO negative pressure wound therapy was granted widespread coverage, and the South Korean 
Health authority granting a 10% price increase for InterTAN citing evidence presented in this 
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thesis. The strengths and limitations of this thesis was highlighted and recommendations 
suggested for future research. 
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1 Chapter 1: Introduction 
Health care systems around the world are under increasing financial pressures. With the 
exponential growth in the introduction and uptake of health technologies, governments 
and health care providers are challenged to use available resources as efficiently as 
possible in order to maximize population health. As such, providers are expected to deliver 
higher-quality health care for patients with the same amount of money or at times less, 
(Hawkes, 2012). This has placed greater emphasis on purchasing interventions, which 
provide the best health outcomes at less costs, thus necessitating that choices are made 
between competing alternatives (Drummond et al., 2005).  
Currently, the most common method to facilitate choice between competing medical 
technologies or devices is a health technology assessment (HTA), which is used to ascertain 
the relative costs and benefits of health care interventions (Ciani et al., 2017). The 
information gained from HTA is then used to aid priority setting by supporting clinical, 
reimbursement, or coverage decisions (EUnetHTA, 2015; Ciani et al., 2017). The European 
Network of Health Technology Assessment (EUnetHTA) has recommended that currently 
established evidence assessment methodology used in pharmaceutical evaluations be 
applied in medical devices. However, the Advanced Medical Technology Association 
(AdvaMed) observed that, given the diversity in medical technologies, a “one-size-fits-all” 
approach to evidence, would be unsuitable and impractical (Miller, 2017), thus, a more 
flexible approach to evidence evaluation should be considered.  
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In order to address the increasing needs for evidence, manufacturers have responded by 
hiring professionals with competencies in health economics and outcomes research 
(HEOR). HEOR departments within manufacturing organisations provide evidence for a 
payer audience through groups such as HTA bodies or Pricing and 
Reimbursement/Formulary committees. Clinical and health economic evidence is needed 
to support the value proposition of health care interventions. This proposition, in turn, 
must consider the impact of the intervention on health outcomes and the economic 
consequences of implementing the intervention.  
1.1.1 Motivation for research 
I have been working in the field of Health Economics and Outcomes Research (HEOR) for 
the past 16 years. In the past 7 years, I have specialised in medical devices, and my research 
has focused on wound care and orthopaedic trauma devices. My research interest in 
wound care and orthopaedics has been informed by the business needs of my employer 
Smith and Nephew Inc, who operates a three-franchise business model focusing on: 
Wound care, Orthopaedics, and Sports medicine. The research that I conducted as part of 
my employment forms the basis of my thesis and I used examples from wound care and 
musculoskeletal (MSK) disorders, to demonstrate the clinical and economic value of the 
devices to patients, the payers and clinical audience.  
The use of wound care and MSK disorder publications in this thesis was deemed 
appropriate, as the methodology and evidence requirements for the medical devices are 
similar. Both wound care and MSK disorders require careful appraisal of clinical evidence 
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as they impose a major cost burden to society and healthcare systems which will grow 
further as the global population continues to age. The clinical evidence is then used to 
inform the economic modelling to generate cost-effectiveness evidence. The totality of 
clinical and cost-effectiveness evidence together with other considerations, is then used 
to inform coverage and reimbursement decisions, which optimises the health outcomes of 
the patients, budgets for payers and profits for manufacturers. 
1.1.2 Medical devices and the challenges of conducting HTA 
The term medical device is defined by the World Health Organisation, as an article, 
instrument, apparatus or machine that is used in the prevention, diagnosis or treatment 
of illness or disease, or for detecting, measuring, restoring, correcting or modifying the 
structure or function of the body for some health purpose. Typically, the mechanism of 
action of a medical device is physical which is not achieved by pharmacological, 
immunological or metabolic means (WHO Medical Devices Technical series, 2011). Medical 
devices therefore, cover a huge range of healthcare products and equipment such as 
surgical gloves, wound care dressings, orthopaedic implants and many other instruments. 
The thesis will adopt this definition, and also sometimes will use the term medical 
technologies as a synonym.  
Medical devices have unique characteristics which can present challenges in performing 
Health technology Assessment and hence usually have a lower bar of evidence 
requirements when compared to pharmaceuticals (Miller, 2017). For instance, there is a 
learning curve challenge when working with medical devices owing to the interaction 
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between the operator and the device. The learning curve affects the clinical performance 
of new devices when compared to standard care since clinicians take time to reach levels 
of competency and proficiency when using new devices. This makes it difficult for early 
studies to find true difference between new device and the standard of care (Sorenson et 
al., 2011; Taylor and Iglesias, 2009). As a result, medical devices work only if they are used 
correctly and their effectiveness relies on the skills and experience of the physician using 
them among other factors.  
In addition, it is difficult to conduct RCTs of medical devices due to few candidate patients 
of a new device or the learning curve effect where clinicians are not certain of the merits 
of the new device especially if they are invasive (Sorenson et al., 2011). Furthermore, the 
small sample sizes and short follow up makes it difficult to detect statistically significant 
differences and demonstration of the true value of the device which increases the 
uncertainty associated with the new medical devices (Taylor and Iglesias, 2009). 
A further challenge in conducting HTA in medical devices is genericization and class effect, 
that is assuming a class effect. This can be a flawed assumption since devices differ in their 
mode of action and properties, making it difficult to extrapolate clinical evidence even of 
similar brands (Drummond et al., 2009; Sorenson et al., 2011). There is also a challenge of 
rapid incremental innovations for medical devices. This impacts on the ability to conduct 
RCTs which usually require longer periods to complete by which time the device will be 
obsolete (Drummond et al., 2009; Taylor and Iglesias, 2009). For these and other reasons, 
it therefore important to consider a variety of sources of evidence when evaluating the 
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clinical and cost effectiveness of medical devices. This can include both RCTs, observational 
evidence from registry studies, or real-world evidence to ensure timely access of 
innovative technologies for patients. Equally, when medical devices have gathered enough 
evidence, rigorous assessment of evidence should be conducted similar to the one for 
pharmaceuticals. 
1.1.3 Reimbursement  
In this thesis, reimbursement is defined according to Bruen et al., (2016) which is an 
umbrella term for the policies and practices that define the terms of coverage and payment 
for a medical device, it encompasses the implicit or explicit decisions by payers (such as 
Medicare and Medicaid in the United States of America (US), United Kingdom National 
Health Service (UK NHS). The policies establish whether or not a device delivers sufficient 
benefit to be covered, the terms under which a device is covered and define the method 
of payment to the provider, dispenser or supplier of a healthcare technology (Bruen et al., 
2016)  
1.2 Overall aim of the thesis 
Using previously published work by the researcher, this thesis evaluates the clinical and 
economic evidence used to inform coverage and reimbursement decisions for medical 
devices using examples from wound care and MSK disorders. 
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1.2.1 Objectives of the thesis are to: 
1. Provide an overview of the types of clinical data and methods used to synthesize 
the evidence for coverage and reimbursement decisions making with reference to 
wound and MSK disorders 
 
2. Give an overview of the main types of economic evaluations and economic 
modelling techniques used to support coverage and reimbursement decisions in 
both wound and MSK disorders 
 
3. Critically appraise each of the author’s published studies, noting the incremental 
contribution to the body of knowledge and the influence of the new insights in the 
field 
 
4. Draw conclusions and suggest areas of future research 
 
1.3 Thesis Overview 
This thesis presents clinical and economic evidence used to inform coverage and 
reimbursement decisions of medical devices. It is based on 8 of the researcher’s works 
published between 2017 and 2018: 5 in acute wound care and 3 in MSK disorders (in 
particular, orthopaedic hip fractures).  
Chapter 1: Introduction and the aims of the PhD thesis.  
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Chapter 2: Highlight the burden of wound care and MSK disorders, with special reference 
to burn wounds, surgical site complications, and hip fractures, as well as the existing 
evidence gaps. 
Chapter 3: Provides a brief overview of the types of clinical and economic evidence used 
for medical decision making. 
Chapter 4: Examines the clinical effectiveness of advanced wound care devices, with a 
focus on silver dressings used in burn care, using systematic review and indirect treatment 
comparison methods.  
Chapter 5: Examines the cost-effectiveness evidence in wound care, in particular 
1. Cost-effectiveness evidence from burn wound care using clinical effectiveness 
publications presented in Chapter 4. 
2. Cost-effectiveness evidence from single use negative pressure wound therapy 
device to prevent surgical site complications using clinical evidence from 
randomised controlled trials.  
Chapter 6: Examines the clinical effectiveness evidence of orthopaedic implants in 
managing patients with trochanteric fractures, with a special focus on intramedullary nails. 
Chapter 7: Examines the cost-effectiveness of intramedullary nails in patients with 
trochanteric fractures using evidence from the clinical effectiveness publications in 
Chapter 6.  
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Chapter 8: Provide a key summary of the research and conclusions highlighting 
implications for patients, clinical practice, healthcare policy, and recommendations for 
future research. 
1.4 Conclusion 
This chapter has introduced the motivation, and highlighted the motivation, aims and 
objectives of the thesis.  
The following chapter will provide background on the burden of wounds, with particular 
reference to burn wounds and surgical site complications. Furthermore, evidence on the 
burden of MSK disorders, with special reference to hip fractures will be discussed including 
evidence gaps for both wound care and MSK disorders.  
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2 Chapter 2: Background to wound care and musculoskeletal 
disorders  
2.1 Introduction 
Chapter 1 outlined the aim of the thesis and the context as to why it is necessary to have 
good clinical and cost-effectiveness evidence to support clinicians and payers in their 
objective efforts to optimise health outcomes for their patients. This chapter provides 
background to wounds and MSK disorders, including the rational for conducting this 
research by outlining the evidence gaps. 
2.2 Burden and costs of wound care  
According to Guest et al., (2017), wounds are managed across the spectrum of different 
healthcare disciplines, including general practice, specialist physicians, and allied 
healthcare practitioners. Wounds can either be chronic, (those that have not progressed 
through the normal process of healing and are open for more than a month) or acute, 
(those wounds that heals uneventfully with time) (Sen, 2019). Although the true burden of 
wounds is unknown, they have a rough prevalence estimates in developed countries of 
between 1-2% of the general population (Guest et al., 2017). 
Between 2012 and 2013, the United Kingdom’s National Health Service (UK NHS) managed 
an estimated 2⋅2 million patients with a wound at an estimated annual cost of £5.3 billion 
including associated comorbidities (Guest et al., 2017). Of the reported 2.2 million wounds, 
4% were burn wounds and 11% were surgical wounds respectively. In the United States 
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(US) nearly 14% of Medicare beneficiaries had at least one type of wound or infection, and 
surgical infections were the largest prevalence category (4.0%). Total Medicare spending 
estimates for all wound types ranged from $28.1 to $96.8 billion (Nussbaum et al., 2018). 
This thesis focused on burn and surgical wounds to illustrate how comparative clinical and 
cost-effectiveness evidence can be or has been used to inform coverage and 
reimbursement decisions in healthcare.  
2.3 Burn wounds 
Burns are a common type of traumatic injury that causes considerable morbidity and 
mortality (Brusselaers et al., 2013). Globally burn injuries account for an estimated 
180,000 deaths annually and non-fatal burns are a leading cause of morbidity, including 
prolonged hospitalization, disfigurement, and disability (WHO Burn Fact Sheet, 2018). In 
the United States alone, over 400,000 people require medical care for burn injuries each 
year, leading to 40,000 hospitalisations costing around $1 billion per year (American Burns 
Association, 2016). Furthermore, in the United Kingdom, one study found that a burn 
patient costs at least twice as much compared with other hospitalised patients (Pellatt et 
al., 2010). Indirect costs of burn wounds, such as lost wages and prolonged care for 
emotional trauma, also contribute to the socioeconomic burden.  
Treatment of burn injuries is aimed at controlling infection which remains the leading 
cause of morbidity and mortality. Treatment goals also include promoting healing, with 
good aesthetic outcomes and thus improving the quality of life of the patients (Wasiak et 
al., 2013). Topical antimicrobial therapy is mainly used to treat burn wounds, and silver-
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containing products are the preferred choice of treatment given their impact on infection 
control (Wounds International 2012, EBA 2017). Silver sulfadiazine (SSD) has been the 
standard treatment for partial-thickness burns, however, SSD has well documented 
challenges, such as the need for frequent dressing changes (Atiyeh et al., 2007; Brusselaers 
et al., 2010; Wounds International 2012; EBA, 2017). Newer, improved silver delivery 
systems designed to overcome some of these problems have become available over the 
past few decades. These include nanocrystalline silver (ACTICOAT™ Smith & Nephew Hull, 
UK), silver hydrofiber dressing (AQUACEL® Ag, ConvaTech, Bridgewater, NJ), and silver-
impregnated foam dressings (Mepilex® Ag, Mölnlycke, Göteborg, Sweden), collectively 
referred to as “newer silver dressings” in this thesis.  
2.3.1 Evidence gaps in burn wound care 
A systematic literature review was conducted from various medical databases such as the 
MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews, assessing the use of 
silver dressings in burn wounds, in particular the use of SSD compared with ACTICOAT and 
other newer silver dressings. These databases are preferred as they contain up-to-date 
and relevant medical literature (Bramer et al., 2017). One systematic review and meta-
analysis (Gravante et al., 2009) was identified which compared ACTICOAT with SSD, and 
concluded that ACTICOAT was superior with regards to infection control and pain in burn 
patients. However, evidence on length of stay (LOS) was not conclusive and the incidence 
of surgical procedures was not reported in this study. Another review of ACTICOAT 
evidence (Khundkar et al., 2011) found that ACTIOAT had superior antimicrobial activity 
and reduces healing time when compared to another available silver dressings. 
12 
 
Furthermore, no studies were identified which compared the newer silver dressings 
against each other both from a clinical and cost-effectiveness point of view in patients 
following burn injury, in spite of the fact that these dressings are widely used in clinical 
practice.  
The European Burns Association’s (EBA) clinical practice guidelines, which according to 
Paprottka et al., (2016) have the most comprehensive treatment recommendations, offer 
no definitive guidance as to which silver dressing should be preferred over the other when 
managing burn patients. Rather, the EBA advises clinicians to ‘be creative in choosing silver 
burn dressings because there is no direct clinical evidence to support the choice of one 
dressing over another’ (EBA, 2017 :39). 
The research presented in this thesis addressed this evidence gap by comparing the clinical 
and cost-effectiveness of newer silver dressings in burn patients. This was achieved by 
conducting systematic literature review and meta-analysis of all available comparative 
evidence of randomised controlled trials (RCTs) and observational studies). The research 
further ranked the silver dressing according to cost-effectiveness in order to offer 
unambiguous guidance to clinicians and payers as to which silver dressing should be used 
first clinically and reimbursed. 
2.4 Surgical site complications 
One of the main goals of wound care after surgery is to ensure that the wounds heal rapidly 
without complications (such as infections and dehiscence) according to the World Union 
of Wound healing Societies (WUWHS, 2016). The most common surgical site complications 
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(SSCs) reported are surgical site infections (SSIs), dehiscence, seroma, and haematoma, 
which complicate 2-5% of surgeries in the United States and about 6% globally (WHO SSI 
Report, 2016; WUWHS, 2016; Curcio et al., 2019). A person with an SSI has a poor quality 
of life and has a 2- to 11-fold risk of mortality (WHO SSI Report, 2016; WUWHS, 2016). 
SSCs are often associated with protracted wound healing process resulting in increased 
length of hospital stay, higher rates of readmissions, and increased episode of care costs 
(WHO SSI Report, 2016; WUWHS, 2016). In the European Union (EU), SSIs cost the health 
care system between 1.4 and 19.1 billion Euros per year, whereas in the United States it 
costs between $5.94 to $14 billion dollars per year (Leaper et al., 2004; Nussbaum et al., 
2018). These cost estimates do not include patients and caregivers’ costs, and are 
therefore an under-representation of the true total cost to society. 
Many strategies have been introduced to control SSI, including antibiotics prophylaxis, 
post-operative wound care dressings, and traditional negative pressure wound therapy 
devices. Negative pressure wound therapy applies controlled suction to a wound using a 
suction pump that delivers intermittent, continuous, or variable negative pressure evenly 
through a wound filler (foam or gauze) (WUWHS, 2016). There are a variety of smaller, 
single-use negative pressure wound therapy (sNPWT) devices currently being used 
following surgical procedures to prevent SSIs. However, there has been slow adoption of 
these sNPWT devices, as clinicians and particularly payers demand evidence of their clinical 
performance and in particular cost-effectiveness evidence of sNPWT which is particularly 
lacking. 
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2.4.1 Evidence gaps in the use of single-use negative pressure wound therapy (sNPWT) 
following surgery to prevent SSCs 
Although there are a number of sNPWT used in the management of SSIs following surgery, 
this research focuses on the cost-effectiveness evidence of one of the devices, (PICO™, 
Smith & Nephew, Hull, UK). Following a review of the literature, there was an abundance 
of clinical evidence comparing PICO with standard care and no health economic 
evaluations on the use of PICO following surgical procedures. Health economic evaluations 
have become important in supporting the use and adoption of medical devices by 
clinicians, payers and policy makers, in today’s in resource constrained healthcare systems.  
The research presented in this thesis has addressed the health economic evidence gap of 
PICO in the prevention of SSIs in patients following cardiothoracic and orthopaedic surgery. 
PICO is indicated in a number of surgical procedures, and additional work was conducted 
in other surgical procedures which was not included in this thesis as it was still in abstract 
form. The research presented in this thesis has had demonstrable impact as evidenced by 
the widespread coverage of PICO by the UK NHS and increase in global sales of the device. 
The UK’s National Institute for Health and Care Excellence (NICE) concluded that, 
“Evidence supports the case for adopting PICO negative pressure wound dressings for 
closed surgical incisions in the NHS,” after considering evidence from Study 4 and 5 and 
additional research which I conducted (Nherera et al., 2019a; Nherera et al., 2019b). 
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2.5 Burden and costs of musculoskeletal disorders  
MSK health refers to the health of the locomotor apparatus, which enables the individual 
to independently perform daily activities without functional restrictions (Woolf, 2015; 
Briggs et al., 2018). MSK disorders range from inflammatory joint diseases such as 
rheumatoid arthritis, to fragility fractures, and are characterised by pain and reduced 
physical function (Woolf, 2015; Briggs et al., 2018). Furthermore, MSK disorders 
significantly impair patients’ health-related quality of life (HRQoL), as they normally 
experience loss of mobility and independence, as well as higher mortality rates (Beaudart 
et al., 2017). 
The prevalence estimates vary with respect to age and MSK condition. However, evidence 
suggests that 1 in 3 people worldwide live with a chronic, painful MSK condition (Cauely et 
al., 2013; Papadimitriou et al., 2017). In the United States, it is estimated that 1 in 2 adult 
Americans live with a MSK disorder (Woolf, 2015; Briggs et al., 2018), which cost US 
taxpayers approximately $213 billion in 2011 (Briggs et al., 2018). Despite the high 
prevalence and costs, MSK disorders have not received similar attention as that of other 
non-communicable diseases, such as heart diseases and obesity. President George W. Bush 
proclaimed the years 2002–2011 as the United States Bone and Joint Decade, providing 
national recognition to the fact that MSK disorders and diseases are the leading cause of 
physical disability in the country (https://www.govinfo.gov/content/pkg/CFR-2003-title3-
vol1/pdf/CFR-2003-title3-vol1-proc7533.pdf). In 2006, the Royal College of General 
Practitioners estimated that over 1 million adults in the United Kingdom consult their 
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general practitioner each year with symptoms of osteoarthritis. Hospital admissions have 
been increasing due to hip and knee arthritis. In 2010/11, there were 207,041 such 
admissions, representing an 80% increase above that seen a decade prior (Chen et al., 
2012). 
Amongst the many MSK disorders, hip fractures are considered to be a major public health 
problem in terms of patient morbidity, mortality, and costs to health and social care (Swart 
et al., 2014). Worldwide, hip fractures are estimated to surpass 6.3 million by 2050. In the 
United States alone, the number of hip fractures is estimated to increase from about 
320,000 per year to 580,000 by 2040, with healthcare costs exceeding $10 billion per year 
(Papadimitriou et al., 2017). The rate of hip fractures is expected to continue to rise with 
the corresponding increase in life expectancy (Cauely et al., 2013; Papadimitriou et al., 
2017). A similar trend is observed In the European Union, where there were an estimated 
600,000 hip fractures costing €20 billion to the health system in 2010 (Cauely et al., 2013; 
Leal et al., 2016).  
Hip fractures can be classified into intracapsular or extracapsular fractures, depending on 
whether the fracture is inside (intracapsular) or outside (extracapsular/intertrochanteric) 
the joint capsule of the hip, with surgical management the best treatment option for both 
(Bateman et al., 2012). Intertrochanteric fractures are further classified as stable or 
unstable, and are managed with either a compression hip screw or an intramedullary (IM) 
nail. According, UK NICE guidelines and the American Academy of Orthopaedic Surgeons 
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(AAOS), IM nails should be used in unstable intertrochanteric fractures (Bateman et al., 
2012).  
2.5.1 Evidence gaps in use of intramedullary (IM) nails in unstable intertrochanteric 
fractures 
The literature review revealed that there are a number of IM nails currently being used in 
patients with unstable intertrochanteric fractures, yet there is no guidance as to which 
among the IM nails will optimise patient benefits due to lack of definitive published clinical 
and cost-effectiveness evidence. For payers, the goal would be to grant coverage and 
reimburse the IM nails that will both optimise patient outcomes and reduce the cost of 
treating hip fractures.  
Due to the lack of definitive clinical and cost-effective evidence supporting the use of one 
IM nails over another in patients with unstable intertrochanteric fractures, this author 
conceived and conducted research to address this evidence gap. The thesis therefore 
presents comparative evidence that will help payers and clinicians choose the most 
clinically and cost-effective IM nail in patients with intertrochanteric fractures. The 
evidence presented has had demonstrable impact already in South Korea, where InterTAN 
nail was granted a 10% increase in price and increase in sales of the device as reported in 
Section 7.8 and 8.8. of the thesis.  
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2.6 Chapter summary  
Overall, the burden of wound care and MSK disorders is huge and only expected to rise 
due to aging and chronic diseases. Clinically and cost-effective interventions for wound 
care and MSK disorders are therefore imperative to reduce the sociological and economic 
burdens. Producing such evidence can aid priority-setting and obtain optimal benefit from 
limited resources for the benefit of patients, payers, and manufactures alike. This chapter 
in addition to outlining the burden of wound care and MSK disease, also identified 
evidence gaps which forms the basis of this thesis  
The next chapter will describe the types of clinical and economic evidence used to inform 
coverage and reimbursement decisions for medical devices.  
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3 Chapter 3: Types of evidence for coverage and reimbursement 
decision making in medical devices 
3.1 Introduction 
Decisions that shape health care should be grounded on a reliable evidence base. Archie 
Cochrane posed 3 critical questions for assessing clinical evidence for decision-making 
purposes. Firstly, “can it work?”; secondly, “will it work?”; and lastly, “Is it worth it?” 
(Fineberg, 2010). This chapter will briefly address all the 3 questions, and conclude by 
highlighting the types of evidence applicable to this thesis.  
3.2 Types of clinical evidence for coverage and reimbursement decision 
making 
Clinical evidence for medical devices is used for different purposes, such as approval by 
regulators, coverage and payment policies by payers, clinical decision making by clinicians, 
and for manufacturers to demonstrate the value of new medical devices (Dreyer et al., 
2010; Miller, 2017). There are a number of ways of generating this evidence via primary or 
secondary data sources. Primary data sources include any study design, qualitative or 
quantitative, where data are collected from individuals or groups of people, whereas 
secondary sources do not collect data directly from patients (Dreyer et al., 2010).  
The traditional clinical research model depicts evidence as a pyramid, with the strongest 
level of evidence (systematic reviews and meta-analysis) displayed at the top, and what is 
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considered the weakest evidences (ideas and opinions) at the bottom. This ranking of 
studies according to their research designs provides a guide to the strength of the 
evidence, and also indicates the confidence the end user can have in the research findings 
(Evans, 2003). Accordingly, this ranking of evidence has placed more emphasis on 
effectiveness of interventions and, as a result, randomised controlled trials have been 
commonly viewed as providing the highest level of evidence. 
3.2.1 Randomised controlled trials (RCTs) 
For treatment decisions, there is a consensus that the most reliable primary study type is 
the RCT. This type of study answers Cochrane’s question “can it work?,” which is about 
efficacy under controlled and replicable conditions (CADTH, 2017; Miller, 2017). In RCTs, 
patients are randomly assigned to have either the treatment being tested, or a comparison 
treatment using a strict inclusion criterion. RCTs ensure that the groups formed are similar 
in all aspects through randomisation except for chance differences (CADTH, 2017; Higgins, 
2011). Randomisation enhances the internal validity of the studies, which is the extent to 
which the observed difference in outcomes between the study groups can be attributed to 
the intervention rather than other factors (Higgins, 2011).  
The advantage of an RCT design is that it minimises selection biases and confounding, 
which are seen as threats to the internal validity of a study (Speith et al., 2016). Selection 
bias is defined as a systematic error in creating intervention groups, causing them to differ 
with respect to measured or unmeasured baseline characteristics, whereas confounding is 
a situation in which the estimated intervention effect is biased, because of some difference 
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between the comparison groups apart from the planned interventions which can predict 
the outcome of interest (Dreyer et al., 2010; Speith et al., 2016).  
The main limitation of RCTs is the poor external validity of their findings; that is, the results 
cannot easily be generalisable outside of the population that was studied because of their 
strict inclusion and exclusion criteria (Dreyer et al., 2010; Speith et al., 2016). It is not 
always possible to blind patients to treatment allocation when doing a study on dressings 
or surgical implants. Furthermore, RCTs are costly to conduct and focus on short-term 
effects of an intervention among a small population, and therefore relevant long-term 
outcomes are not captured (Dreyer et al., 2010; Speith et al., 2016). In the study of medical 
devices, there are further issues with timing of RCTs. Such studies normally take 2-3 years 
to complete, by which time the device will be outdated, as they are usually quickly 
produced based on incremental technological enhancements (Tarricone et al., 2017; 
Drummond et al., 2018). When it is not feasible or ethical to conduct RCTs, other forms of 
research that are less costly and quicker to conduct, such as observational studies, should 
be considered.  
3.2.2 Observational studies 
The assessment of a healthcare intervention must go beyond whether the intervention can 
work under ideal circumstances, to an understanding of its effectiveness, that is, how well 
the medical devices work in broad patient populations (Tarricone et al., 2017). This type 
of evidence addresses the second question posed by Archie Cochrane, ‘will it work?” 
Observational studies include the patient populations which are usually excluded from the 
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RCTs due to age, gender, or presence of comorbid conditions (Dreyer et al., 2010; Tarricone 
et al., 2017). They are therefore capable of assessing “real-world” health and economic 
outcomes to help guide decision making for patient care in a timelier manner, which 
increases external validity of the study findings. 
Despite the increased external validity offered by observational studies, they do have the 
inherent limitations of bias and confounding. This is attributed to lack of randomisation, 
which often leads to a perception by clinicians and payers that observational studies are 
an inferior study design when compared with RCTs (Tarricone et al., 2017). However, 
modern analytical methods are available that minimise the impact of bias and 
confounding, such as matching or propensity score matching, which ensures equal 
representation of subjects with certain confounders among study groups. (Tarricone et al., 
2017) 
3.2.3 Systematic literature review 
In general, a single study does not always provide a conclusive answer to a clinical question 
and hence the need to conduct a number of studies and summarise them together to 
increase confidence in clinical findings. One way of summarising evidence is conducting a 
systematic literature review (SLR), which summarises the results of available literature, 
and provides a high level of evidence on the effectiveness of medical devices (Lau et al., 
1997; Glasizou et al., 2014). A SLR involves designing a comprehensive search strategy, 
which makes it explicit how the authors attempted to find all relevant studies and judged 
their individual scientific quality (Lau et al., 1997). SLR differ from a narrative review which 
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tend to be descriptive in nature and do not involve a systematic literature search, which is 
prone to selection bias (Uman, 2011). 
The results of the SLR can be summarised qualitatively or quantitatively. When the studies 
identified by the SLR are very different (heterogeneous), it is best to summarise the results 
qualitatively, whereas if they are sufficiently homogeneous, then a meta-analysis is 
recommended (Hunter et al., 2002).  
3.2.4  Meta-analysis  
Systematic literature reviews often include a meta-analysis when the included studies are 
sufficiently homogeneous (Hunter et al., 2002). Meta-analysis is defined as a set of 
statistical methods used to combine the results of two or more independent studies to 
derive a single, more precise estimate of effect, in order to evaluate the therapeutic 
effectiveness of medical devices (Egger et al., 1997; Egger et al., 2002; Uman, 2011). Meta-
analysis helps to address controversy of conflicting findings from individual RCTs or 
observational studies.  
The advantages of both a SLR and meta-analysis is that they use explicit methods which 
are intended to minimize bias. SLRs and meta-analysis are quick to perform, and less costly 
than primary studies, and when properly performed, they provide a powerful summary of 
the evidence (Higgins et al., 2019). The main limitation of SLRs and meta-analysis is that 
their findings are only as good as the studies that they include. Poorly conducted studies 
may potentially give misleading or biased results. A further limitation is some of the studies 
becomes outdated by the time they are published. For instance, a study by Shojania et al 
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(2007) found that 7% of SLRs and meta-analysis needed updating at the time of publication, 
4% within a year, and 11% within 2 years.  
3.2.5 Summary of the types of clinical evidence 
There are other types of clinical evidence which are not the focus of this thesis, such as 
Real-World Evidence which are gaining traction with payers, regulatory bodies and 
clinicians. It is clear that there is no type of clinical evidence that can answer all the 
relevant questions around efficacy and effectiveness of medical devices and therefore a 
one size fits all approach to clinical evidence is not advocated. Rather, the choice of 
evidence types should reflect the decision problem at hand. This thesis will focus on clinical 
evidence derived from both RCT and observational evidence using SLR and meta-analysis 
methods to summarise the available clinical evidence, to assist clinicians, payers and policy 
makers in their desire to optimise patient outcomes and reduce budgetary spend. 
3.3 Economic evaluation 
Section 3.2 above took a relatively narrow view of evidence, focusing predominantly on 
evidence types used for clinical decision making. Although such a focus is necessary to 
define the effect of a medical device, it is not sufficient to provide the breadth of evidence 
that clinicians and policy makers need to derive recommendations for coverage and 
reimbursement decisions (Eccles et al., 2000). As mentioned in Section 3.1 above, 
Cochrane’s third question (“Is it worth it?”) requires a consideration of costs. Incorporating 
such cost considerations into clinical evaluations has been advocated by many national 
bodies tasked with making coverage and reimbursement decisions, such as the United 
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Kingdom’s NICE, the Institute for Quality and Efficiency in Healthcare (IQWiG) in Germany, 
the French National Authority for Health (HAS) in France, and the Canadian Agency for 
Drugs and Technologies in Health (CADTH) in Canada (Hoaglin et al., 2011). Consequently, 
decision makers and health care practitioners are increasingly demanding evidence of 
economic value for healthcare interventions. Conducting high-quality economic 
evaluations has therefore become a priority in coverage and reimbursement decision-
making process (Drummond et al., 2018).  
Economic evaluation is defined as the comparative analysis of at least two or more 
interventions, in this case medical devices, in terms of their costs and consequences 
(Drummond et al., 2005). Economic evaluation has become an important tool in informing 
coverage and reimbursement decisions, especially in Europe and other publicly funded 
health systems such as those in Australia and Canada.  
There are a number of economic evaluation methods in health care. Two commonly used 
approaches are cost-effectiveness analysis (CEA) or cost-utility analysis (CUA). The choice 
of technique in economic evaluation should reflect the decision that the economic 
evaluation is designed to inform (Hoang et al., 2016). This section briefly considers the 
different types of economic evaluations and concludes by outlining the techniques that are 
applicable in this thesis. 
3.3.1 Cost utility analysis (CUA) 
The cost-utility analysis (CUA) is a type of economic evaluation that considers the 
improvement in quality of life and length of life following the use of a medical device for 
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the amount of resources used to generate those benefits (Drummond et al., 2005; Mathes 
et al., 2013). Clinical studies generate the increase in length of life as a result of the medical 
device. The length of is then adjusted for the quality of life by an index called “utility,”. 
Utility is the measure of relative value or preference placed on a specific health status or 
an improvement in health status (Torrance, 1986). The most commonly used measure of 
utility is the quality adjusted life year (QALY), which aggregates the morbidity and mortality 
effects of a medical device (Torrance, 1986; Drummond et al., 2005).  
CUA is preferred by regulatory authorities because it uses explicit methodology for 
calculating QALYs, which facilitates the comparison of results of economic evaluations 
across programmes of work (Drummond et al., 2005; Heintz et al., 2016). However, a CUA 
is not always possible to conduct, for instance, when information on quality of life is not 
available, it is impossible to calculate QALYs. There are also conflicting ideas about how to 
incorporate the patient’s willingness to pay in decisions to reimburse new treatments 
(Drummond et al., 2005; Heintz et al., 2016). In such cases a cost-effectiveness analysis 
can be conducted which does not require the quality of life measures. 
3.3.2 Cost-effectiveness analysis (CEA) 
CEA is an economic study design in which the consequences of different interventions are 
measured using a single outcome, usually in ‘natural’ units (for example, life-years gained, 
or complications avoided) (Drummond et al., 2005). By comparing the cost and 
effectiveness (outcomes) of two or more devices, the decision maker is able to evaluate 
the benefits and limitations of new devices compared with the standard of care.  
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Results of both CEA and CUA are expressed as an incremental cost-effectiveness ratio (ICER), 
which is the ratio of the difference in cost between devices being compared divided by the 
difference in benefits measured either in natural units for CEA or QALY for CUA (Drummond et 
al., 2005). However, the results of a CEA can only be compared with the results of other devices 
that are expressed in the same outcome measure/unit and is unidimensional, as only one domain 
of benefits can be explored at a time.  
3.3.3 Other types of economic evaluation  
There are other types of evaluations of healthcare resources, which are not the focus of 
this thesis. The cost-minimization analysis (CMA) is utilised in situations where alternative 
devices have been proven to deliver similar clinical benefits, and therefore focuses on the 
acquisition cost of the devices. CMA is considered to be too simplistic (Briggs and O'Brien, 
2001; Drummond et al., 2005). The cost consequence analysis (CCA) quantifies the clinical 
benefits in a disaggregated form and the associated resource impact. In a CCA the decision 
makers form their own opinion on the relevance and relative importance of different 
outcomes and their costs to the decision being considered (Drummond et al., 2005). 
Finally, the cost-benefit analysis (CBA) values costs and outcomes in monetary terms. CBA 
considers all direct and indirect costs of healthcare; however, the method is 
computationally difficult and there are ethical issues regarding assigning monetary values 
to health outcomes (Drummond et al., 2005).  
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3.3.4 Modelling techniques 
Modelling is a decision analytic tool used within economic evaluation methods to 
synthesise the best available information. The two most frequently used modelling 
techniques are the decision trees and Markov models (Karnon and Brown, 1998; Hoang et 
al 2016). 
3.3.5 Decision trees 
Decision trees, the most widely used form of models in health economics. Decision trees 
consist of pathways representing different sequence of events and their associated 
probabilities (Karnon and Brown, 1998; Hoang et al., 2016). They are a preferred modelling 
technique when the time-frame is short and reoccurring events are not important. The 
main advantage of decision trees is that they are easy to follow and simple to construct. 
Their main limitation is that they are not suitable for modelling recurring events, especially 
those with a longer horizon (Karnon and Brown, 1998; Drummond et al., 2005; Hoang et 
al., 2016). 
3.3.6 Markov models 
A Markov model is an analytical framework that consist of a set of health states that are 
mutually exclusive and represent all possible consequences of different medical device 
interventions (Sonnenberg and Beck, 1993; Hoang et al., 2016). Since health states are 
mutually exclusive, the simulated individuals can only be in one state at a time as defined 
by the cycle length and the speed of movement between health states is determined by 
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transition probabilities (Sonnenberg and Beck, 1993; Karnon and Brown, 1998; Kuntz et al., 
2013; Hoang et al., 2016).  
Markov models are suitable for modelling clinical problems that occur over a longer time 
horizon, which involve risk over time. The ability of Markov models in handling the time 
component also gives them an advantage over decision tree especially where the 
sequencing of events is important (Karnon and Brown, 1998; Kuntz et al., 2013; Hoang et 
al., 2016). The primary limitation is the assumption known as the “Markovian property or 
memoryless assumption.” This assumption states that the probability of moving from one 
health state to another is dependent on the time spent in that current health state, and 
does not depend on past history (Karnon and Brown, 1998; Hoang et al., 2016). In the real 
world, the ‘Markovian property” does not always hold, as an individual’s past medical 
history can impact on current clinical outcomes. 
There are other modelling techniques that are more complex and are not the focus of this 
thesis, such as individual-based microsimulation and discrete event simulations (DES). 
These models are capable of simulating the life-time trajectories and recording 
participants’ history. The transitions across different states may be conditional on previous 
history that participants have gone through (Hoang et al., 2016).  
In order for the results of an economic analysis to be meaningful, the choice of a modelling 
technique needs to reflect the problem being addressed and its context. This thesis used 
mainly the decision tree approach, because of the short-term nature of the data and 
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outcomes collected. Previous models in related areas also utilised decision tree approach 
and, therefore, partly informed the choice to adopt the decision tree approach.  
3.4 Conclusions 
There are different types of evidence, ranging from RCTs to observational evidence to SLRs 
with or without meta-analyses. The choice of evidence ultimately depends on specific 
questions being addressed to assist clinicians and those who make coverage and 
reimbursement decisions. There is no single type of evidence that can provide all the 
answers to a clinical question. Archie Cochrane’s questions “Can it work and for whom” 
are addressed by both RCTs and observational studies, whereas his final question “is it 
worth it” is an economic question.  
Payers and providers should recognize the range of legitimate evidence types. Doing so 
ensures that high-value devices reach their patients in a timely manner. This thesis used 
evidence from systematic reviews and meta-analyses of RCTs and observational studies to 
address the questions of clinical and cost-effectiveness of medical devices using examples 
from wound care and MSK disorders. For the economic analysis, cost-effectiveness and 
CUA using decision trees were conducted.  
3.5 Chapter summary  
The chapter briefly outlined the different types of clinical evidence and types of economic 
evaluations. The thesis used the highest-quality source of clinical evidence, which are the 
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SLR and meta-analysis. For the economic modelling, it adopted the CEA and CUA, the 
preferred methods of many national regulatory bodies.  
The next chapter will examine the clinical evidence of medical devices with a focus on 
wound care, primarily the use of silver dressings in burn wound management.  
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4 Chapter 4: Clinical Effectiveness evidence of silver dressings in 
the management of burn wounds  
In this chapter, two articles are presented describing the clinical evidence of advanced 
wound care products in the management of burn wounds using evidence from a SLR and 
meta-analysis. The EBA’s clinical practice guidelines offer no definitive guidance as to 
which silver dressing should be preferred over the other when managing burn patients. 
Rather, the EBA advises clinicians to ‘be creative in choosing silver burn dressings because 
there is no direct clinical evidence to support the choice of one dressing over another’ 
(EBA, 2017:39). Given the lack of definitive guidance on the use of silver dressings in partial 
thickness burns, Study 1 was conceived to help answer the question around the clinical 
effectiveness of one of the new silver dressings ACTICOAT compared with standard of care 
silver sulphadiazine (SSD). Study 2 considered the use of commonly used newer silver 
dressings in burns compared against each other using indirect treatment comparison 
methods (ITC), as described in Sections 4.5.  
 
4.1.1 Study 1: https://doi.org/10.1016/j.burns.2017.01.004 
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4.2 Description of Study 1 
A systematic literature review and meta-analysis of RCT evidence by Gravante et al., (2009) 
concluded that there was evidence suggesting the superiority of ACTICOAT compared with 
SSD with regard to infection control and pain using evidence from RCTs only. In the same 
study, no definitive evidence was reported with regards to length of hospital stay (LOS) 
and none was reported on the incidence of surgical procedures. Study 1, was conceived 
and aimed to address the efficacy and effectiveness of ACTICOAT compared with SSD using 
all available comparative evidence in burns. In addition to using all available evidence 
(RCTs and observational studies) Study 1, also included outcomes on the need for further 
surgical procedures which was not reported by Gravante et al., (2009), in order to 
determine the most clinically effective treatment strategy and thus guide treatment, 
coverage, and reimbursement decisions.  
The methods of the research consisted of two stages: a) an SLR of all comparative evidence 
and b) a pairwise meta-analysis. For the SLR, searches of RCTs and comparative 
observational studies were carried out from bibliographic medical databases, PubMed, 
EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of 
Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health 
Technology Assessment (HTA) Database, ClinicalTrials.gov, International Clinical Trials 
Registry Platform (ICTRP), and the European Trials Register. This was supplemented by 
searching the references of included studies to ensure the search was as comprehensive 
as possible. The U.S. Agency for Healthcare Research and Quality (AHRQ), the UK Centre 
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for Reviews and Dissemination (CRD) and the International Cochrane Collaboration 
recommend that for optimal searches, one should search MEDLINE, EMBASE, and the 
Cochrane CENTRAL trials register as a minimum (Eden et al., 2011; Bramer et al., 2017). 
This study and subsequent systematic literature reviews reported in this thesis went over 
and above the minimum requirements, using a variety of databases since no single 
database contains all the available literature (Betran et al., 2005). Thus, by being 
comprehensive, I can be confident that the majority if not all of the published studies were 
identified as far as was possible.  
Since ACTICOAT was licensed in 1990, the search was restricted to between 1990 and May 
2015. Outcomes of interest were: incidence of infection, LOS, incidence of surgical 
procedures, and pain. Study quality was assessed by Cochrane risk of bias tool and the 
GRACE checklist for RCT and observational studies, respectively (Higgins et al., 2011; 
Dreyer et al., 2014). The statistical model chosen for meta-analysis was dependent of the 
presence or absence of statistical heterogeneity. Sub-group analysis was performed where 
results were reported by study design.  
After applying the inclusion/exclusion criteria, 9 studies were included in the meta-analysis 
with a total of 1194 patients. The study found that the use of ACTICOAT dressings resulted 
in shorter LOS (p < 0.00001), fewer surgical procedures (p < 0.00001), and reduced 
infection rates (p = 0.005) when compared with SSD. A sensitivity analysis was performed 
using different statistical model, random or fixed effects, and considering study designs 
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separately. The conclusions remained the same, that ACTICOAT offered superior clinical 
outcomes. 
4.3 Evaluation of Study 1 
This study showed that ACTICOAT resulted in less pain, fewer surgical procedures and 
shorter LOS when compared with SSD. The results also confirmed earlier findings of the 
meta-analysis by Gravante et al., (2009). The study by Gravante et al., (2009) found that 
ACTICOAT is significantly associated with fewer infections when compared with SSD (p < 
0.001) and lower pain scores. However, unlike Study 1, Gravante et al., (2009) did not 
report on the outcome of the incidence of surgical procedures and excluded evidence from 
observational studies. 
The approach of combining both RCTs and observational studies ensured that all 
appropriate and useful evidence was included for evaluation. By combing RCT and 
observational evidence, results demonstrate the superiority of ACTICOAT on LOS outcomes 
and incidence of surgical procedures. Focusing on RCT evidence alone can potentially result 
in sub-optimal clinical decisions and recommendations, for example by excluding useful 
observational studies. A different conclusion would have been made regarding LOS or 
incidence of surgical procedures in this study, as evidenced by the EBA 2015 guideline (EBA, 
2015) which concluded there was no difference in LOS based on the then published studies. 
This research has now been used to update the 2017 EBA guideline (EBA, 2017), which now 
states that there is a difference in LOS between ACTICOAT and SSD citing this Study 1, 
which is a positive contribution to policy and clinical guidelines used by clinicians and 
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payers in their routine work. However, this study also noted that the definitions of LOS 
and additional surgical procedures sometimes varied between studies. Future studies must 
be standardised to ensure they will be measuring the same outcome and thereby increase 
confidence in conclusions around the efficacy of the devices being evaluated.  
Furthermore, the method of utilising both RCT and observational studies is a valid 
approach that has been used in other therapeutic areas, such as cardiovascular and cancer 
(Bonovas et al., 2005; Shrier et al., 2007). The approach ensures that a bigger sample size 
is included in the overall analysis, which increases the power needed to detect important 
clinical differences. Regulatory bodies such as the UK’s NICE has endorsed the approach of 
combining RCT and observational evidence in the assessment of medical devices, as 
evidenced by the recently published guidance on the use of negative pressure wound 
therapy following surgical incisions (NICE MTG43, 2019 
https://www.nice.org.uk/guidance/mtg43/chapter/1-Recommendations). The inclusion of 
observational studies also provides comprehensive and generalisable real-world data, 
which is especially useful in the field of burns clinical research where there is a lack of large 
RCTs. However, it is also clear that observational studies have well-documented limitations 
around bias and confounding that may hinder the overall conclusions.  
Another noticeable limitation of the included studies was the small sample sizes, especially 
of the RCTs, which are associated with less precise estimates (Linacre, 1994). With small 
RCTs, there is a danger that the overall analysis is dominated by large observational data 
that are more prone to bias. However, smaller sample sizes in medical device RCTs are an 
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unavoidable reality of clinical research, where it is sometimes difficult to recruit patients 
into studies due to budgetary constraints and type of patients. By conducting a meta-
analysis of small individual studies, the sample size problem is partly addressed, as the 
sample is increased and this increases the power to detect clinically meaningful differences 
between the different silver dressings.  
4.4 Conclusion 
This study has demonstrated the strength and utility of sythensising all available evidence 
to inform coverage and reimbursement decisions of medical devices. The study found that 
ACTICOAT is clinically superior compared with SSD in patients with deep and superficial 
partial-thickness burns, resulting in reduced infections rates, LOS, and need for surgical 
procedures. The study also confirmed previously non-contentious knowledge that 
ACTICOAT reduced infections compared with SSD. This research has already been used in 
updating the EBA 2017 guideline (EBA, 2017), which now states that there is a difference 
in LOS between ACTICOAT and SSD. However, clinical heterogeneity, especially regarding 
definitions of LOS and surgical procedures, was identified as an issue that future studies 
should consider standardising.  
 
4.4.1 Study 2: https://doi.org/10.1111/wrr.12559 
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4.5 Description of Study 2 
During the execution of Study 1, when the inclusion and exclusion criteria was being 
applied, I noticed that there were other silver dressings with evidence comparing their use 
with SSD. It became clear that a multiple technology assessment was necessary to directly 
compare all newer silver dressings against each other and hence the conception of Study 
2.  
Study 2 is a systematic review and an ITC of the commonly used newer silver dressings 
ACTICOAT, AQUACEL AG, and MEPILEX AG in the management of partial-thickness burns. 
Although the EBA’s clinical practice guidelines offers no explicit recommendation to 
support the choice of one dressing over another (EBA, 2017), the results of this study can 
be used as part of the decision tools in recommending one dressing over another in the 
next round of the clinical guidelines. Indirect treatment comparisons methods are 
advocated in situations where there are many competing devices that have not been 
compared directly in clinical studies or such direct evidence is limited or insufficient (NICE, 
2013; CADTH, 2017).  
A systematic literature review was conducted comparing three commonly used newer 
silver dressings (ACTICOAT, AQUACEL AG and MEPILEX AG) via a common comparator 
between the three dressings, which was SSD. The methods were similar to those 
implemented in Study 1 Section 4.2 with regards to the search strategy, endpoints, study 
types, and the population. Pairwise meta-analyses were conducted for i) ACTICOAT 
compared to SSD, ii) AQUACEL AG compared to SSD and iii) MEPILEX AG compared to SSD. 
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Following the pairwise meta-analysis, an adjusted ITC using previously defined methods by 
(Bucher et al., 1997) was then implemented comparing ACTICOAT vs AQUACEL AG, 
ACTICOAT vs MEPILEX AG and AQUACEL AG vs MEPILEX AG. Monte Carlo methods were 
used to rank the probability that each silver dressing was the most effective for each 
outcome that was assessed.  
Following the application of the inclusion/exclusion criteria, nineteen studies met the 
inclusion criteria of which sixteen studies provided data for the pair-wise meta-analysis. 
These included 9 studies (4 RCTs and 5 observational studies; 1194 patients) comparing 
ACTICOAT with SSD; 5 studies (2 RCTs and 3 observational studies; 1001 patients) 
comparing AQUACEL AG with SSD; and 2 RCTs and no observational studies (252 patients) 
comparing MEPILEX AG with SSD in 252 patients.  
The results of this ITC analysis showed that there was no difference in infection control 
and the need for further surgical procedures between the new silver dressings. There was 
statistically significant difference in LOS between the new silver dressings in favor of 
ACTICOAT when compared to AQUACEL AG (p = 0.027) and no difference compared to 
MEPILEX AG (p = 0.207). Furthermore, ACTICOAT resulted in shorter healing time when 
compared to MEPILEX AG (p = 0.03) and no difference when compared with AQUACEL AG 
(p = 0.20). A Monte Carlo simulation, which ranked the performance of each silver 
dressings on each individual outcome, demonstrated that ACTICOAT had the highest 
probability of being the most clinically effective silver dressing followed by AQUACEL AG 
for all the outcomes evaluated. 
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4.6 Evaluation of Study 2 
The study results indicate that amongst the newer silver dressings, ACTICOAT is the most 
clinically effective, resulting in reduced LOS in hospital and non-significant reductions in 
infection and the need for further surgical procedures. These results confirm those of small 
studies comparing ACTICOAT with AQUACEL AG and MEPILEX AG, which found no 
difference in infection control (Vebelem et al., 2014; Gee et al., 2015). Furthermore, a 
study by Gravante and Montone, (2010) also reported that ACTICOAT had the shortest 
healing times compared with other dressings including AQUACEL AG in patients with 
superficial and partial thickness burns further corroborates the findings of Study 2.  
Study 2 is the first ITC comparing all the new silver dressings with rankings for the 
performance of each dressing per outcome evaluated. Although there was no difference 
in infection control, the use of Monte Carlo simulation was able to rank the newer silver 
dressings and identified which was more clinically effective. With regard to all outcomes 
evaluated ACTICOAT had in all cases the highest probability of being the most clinically-
effective burn dressings followed by AQUACEL AG, MEPILEX AG and lastly SSD. The findings 
from the Monte Carlo analysis is useful to inform decision making, in particular when it 
comes to choosing the appropriate dressings for burns. As was pointed out earlier in 
Section 4.1, the EBA could not advise clinicians on the choice of dressing when treating 
burns due to lack of direct evidence. This study helps to address this evidence gap, albeit 
using indirect treatment comparison methods. The latest Burn guidelines (EBA, 2017) were 
published before this research. The evidence presented in Study 2 should therefore be 
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considered in the next update of the EBA guideline to reflect the current state of 
knowledge. The findings of Study 2 were used to inform the cost-effectiveness analysis 
described in Section 5.2. 
This study utilised the classical, validated statistical methods outlined by Bucher et al., 
(1997) for conducting ICT. The strength of the approach is that the estimation of the 
relative effect between treatments was derived from all the information available from 
the network of evidence, which was both RCT and observational evidence. The adjusted 
ITC is the recommended approach by methodologists (Glenny et al., 2005; Song et al., 
2005; Edwards et al., 2009) and national HTA agencies such NICE, as opposed to other 
methods like the so-called naïve approaches or simply comparing point estimates. These 
other methods do not include a statistical analysis to enable quantification of the 
magnitude of difference between interventions (Edwards et al., 2009).  
The inclusion of both RCT and observational studies needs to be acknowledged. This 
strengthens both the internal validity of findings by including RCTs and the external validity 
by including observational studies. However, the advantage conferred by observational 
studies may be eroded by concerns regarding bias in observational studies, especially when 
the observational studies are not well conducted. Observational studies included in this 
study were of moderate-to-good quality, as assessed by the GRACE checklist (Dreyer et al., 
2014), and also had large sample sizes. As policymakers and providers seek to extend 
access to useful devices to patients in a timely manner, innovative methods of data analysis 
such as those described in this study should be embraced.  
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As was the case with Study 1 Section 4.2, clinical heterogeneity is one of the main 
limitations. There was also lack of uniform definition of time to healing/re-epithelialisation 
and surgical procedures, which can have a confounding effect on the outcomes, thereby 
affecting the accuracy of the results. A standadised definition of what constitutes time to 
healing or surgical procedures may be helpful for future studies to allow accurate 
assessment of these outcomes with confidence. However, the International Society of 
Pharmacoeconomic and Outcomes Research task force on indirect treatment comparisons 
and good research practices noted that a degree of relative variation in the patient 
populations and outcome measurement is welcome for comparative evaluations, as this 
reflects real-world clinical situations (Hoaglin et al., 2011). 
4.7 Conclusions 
This study presented the clinical effectiveness of newer silver dressings in patients with 
superficial and deep partial-thickness burns. The results of this ITC suggest that ACTICOAT 
results in statistically significant reduction in LOS, when compared with other newer silver 
dressings. Results were comparable for infection control and the need for surgical 
procedures. Strengths and limitations of the study have been noted and suggestions for 
future research outlined. The outputs of this ITC were used in the economic analysis of 
these dressings, which is discussed in the following chapter.  
4.8 Chapter Summary 
This chapter presented the clinical evidence of silver delivery systems in patients with 
superficial and deep partial-thickness burns. Study 1, Section 4.2 used a meta-analysis 
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approach, whereas Study 2, Section 4.5 used an indirect treatment comparison method, 
which are widely used in clinical research to inform coverage and reimbursement 
decisions. Study 1, Section 4.2 confirmed existing knowledge about superiority of 
ACTICOAT with regards to infection control and pain compared with SSD. In addition, the 
study provided new insights with regard to LOS and surgical procedures, as it 
demonstrated a significant difference between ACTICOAT and SSD. This study has been 
used in the current updated EBA guidelines (EBA, 2017), which now specifically mentions 
that ACTICOAT results in reduced LOS. This is an important contribution to clinical decision 
making and the policy debate around the use silver dressings in burns.  
Study 2, Section 4.5 is the first attempt to compare head to head the newer silver dressings 
in burn care, as currently the evidence compares newer silver dressings to standard of care 
SSD. Current evidence confirms the notion that there is no difference in infection control 
between the silver dressings, however, there is potentially a difference in LOS in favor of 
ACTICOAT. The study provided a ranking of the newer silver dressings in terms of clinical 
effectiveness, with ACTICOAT, AQUACEL AG, and MEPILEX AG ranked first, second, and 
third, respectively. This information can potentially be used to update existing guidance to 
clinicians on choosing appropriate dressing in order of effectiveness, something that 
currently does not exist. The next round of EBA guidelines is currently underway following 
their last meeting in September 2019.  
Research limitations were identified and in particular the need for direct head-to-head 
studies to validate the results of ITC, this will help resolve the uncertainty around the 
44 
 
outcome of infection and impact on the incidence of surgical procedures. Standard 
definitions are needed, especially around time to healing and what constitutes surgical 
procedures. Furthermore, there is an additional need to ascertain cost-effectiveness 
evidence surrounding the question of whether the clinical value conferred by the silver 
dressings was worth paying for, which formed the basis of the next chapters.  
The following chapter will address the economic impact of medical devices used in 
wound care with a focus on burn wound infection and SSCs.   
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5 Chapter 5: Cost-effectiveness evidence of medical devices, the 
case of wound care 
5.1 Introduction 
Ionic silver has been in use for wound healing for many years, in particular the topical 
agents such as silver sulphadiazine (SSD), which according to the World Union of Wounds 
(WUWHS, 2016), is considered the current standard of care for burns. The previous studies 
in Section 4.2 to Section 4.6 demonstrated that SSD is the least clinically effective silver 
dressing in the management of burns, and suggested that ACTICOAT was the most clinically 
effective silver dressing. Previously, there were no published cost-effectiveness studies 
comparing all these silver dressings, despite them being widely used. This study therefore 
sought to estimate the cost-effectiveness of commonly used silver dressings, using clinical 
data outputs generated from an ITC Study 2, described in the previous chapter in Section 
4.6. The chapter further presents two additional cost-effectiveness studies that were 
conducted using data from single RCTs of negative pressure wound therapy used in the 
prevention of SSCs. 
 
5.1.1 Study 3: https://www.woundsresearch.com/article/cost-effectiveness-analysis-
silver-delivery-approaches-management-partial-thickness-burns 
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5.2 Description of Study 3 
A decision analytic model using a decision tree was used to estimate the expected 
outcomes and mean costs of patients from the US health payer perspective, to provide 
clinicians and policymakers evidence on the most cost-effective silver dressing. The 
decision tree methodology was deemed suitable because of the short-term nature of the 
outcomes collected. No discounting of costs and outcomes was necessary due to a shorter 
time horizon. Three health states (healed wound, infected wound and additional surgery) 
were modelled, which were informed by the clinical co-authors (Dr Chris Roberts), an 
experienced microbiologist working in the infection area and (Professor Leena Berg MD), 
who is an experienced burn surgeon. Model data (inputs for standard care including clinical 
effectiveness) were derived from the ITC Study 2 presented in Chapter 4. Other inputs like 
costs and health-related quality of life were obtained from published literature. The study 
ranked the different silver dressings in order of cost-effectiveness. One-way sensitivity 
analyses were conducted to assess the impact of uncertainty on the results of the analysis, 
such as varying the effectiveness of silver dressings around the reported 95% confidence 
intervals (CI). 
The results of the analysis showed ACTICOAT to be a dominant strategy. ACTICOAT resulted 
in lower overall treatment costs and improved clinical outcomes when compared with all 
other new silver dressings (AQUACEL AG, MEPILEX AG and SSD). Furthermore, the analysis 
also showed that AQUACEL AG and MEPILEX AG were cost-effective, when compared with 
SSD. Ranking the dressings in order of cost-effectiveness indicated that ACTICOAT was the 
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most cost-effective dressing, followed by AQUACEL AG, MEPILEX AG, and lastly SSD. The 
results remained cost saving from the US payers’ perspective for ACTICOAT, when model 
inputs were changed in sensitivity analyses suggesting the model is robust.  
5.3 Evaluation of Study 3 
This analysis represents the first cost-utility analysis to be published on new silver 
dressings in patients with partial-thickness burns and therefore adds new insights in this 
therapy area. The study demonstrated that ACTICOAT is the most cost-effective silver 
dressing in patients with partial-thickness burns compared with other newer silver 
dressings. The second most cost-effective silver dressing was AQUACEL AG followed by 
MEPILEX AG. The results were stable when sensitivity analysis was performed such as 
varying the effectiveness of the dressings and their costs. Furthermore, the analysis further 
updates the current knowledge that the new silver dressings are cost-saving from the US 
payers’ perspective when compared with SSD (Silverstein et al., 2011; Shecketer et al., 
2014).  
This analysis was conducted using robust clinical data from an ITC of different silver 
dressings used in the management of patients with superficial and partial-thickness burns. 
The choice of comparators is important in economic evaluations, as cost-effectiveness 
ratios are derived using alternatives, which in some cases include more than one for the 
same indication (Henrickson et al., 2012). The strength of this study is that it considered 
the most commonly used newer silver dressings, which was important, as this study was 
able to rank them according to cost-effectiveness. This ranking information is critically 
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necessary for policymakers and healthcare providers who need to prioritise the use of 
these dressings, according to their incremental cost-effectiveness to optimise patients’ 
outcomes. The findings of this research have been successfully used by Smith and 
Nephew’s marketing team to gain market share including making new marketing claims 
around pain reduction and incidence of surgical procedures. The market share for 
ACTICOAT had been falling behind, and following the publication of this Study 3, the brand 
has been growing steadily from negative growth in 2015 to 6% globally in 2018 (Personal 
communication with Business Intelligence Analysts). The marketing team has started to 
engage key opinion leaders to emphasise and highlight the research findings of Study 3 
and are aiming to influence the upcoming EBA 2020 clinical guideline.  
The study had some inherent limitations. The clinical studies were conducted in different 
healthcare systems, which have different clinical practices. This can potentially confound 
the results of the clinical parameters that were applied in the economic analysis. Also, 
although the use of ITC methods is accepted, direct head-to-head evidence for the 
dressings are warranted in order to verify the results of ITC. Therefore, these results need 
to be interpreted with caution until such direct evidence becomes available and this 
analysis is updated. 
A series of one-way sensitivity analyses were carried out and confirmed that the results 
were robust. However, the study could have benefited from a probabilistic sensitivity 
analysis, which would have quantified the level of confidence derived from the conclusions 
of the economic evaluation (Claxton et al., 2008; Adalsteinsson and Toumi, 2013). Equally, 
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the model only considered costs from the payer’s perspective, an approach that negates 
indirect costs such as productivity, patients and caregiver costs, which might 
underestimate the true cost or savings to society. These limitations, however, are not 
deemed to alter the overall conclusions of the analysis, because it is expected that the 
superior technology would lead to less overall costs whether they are societal or medical.  
Another limitation is the focus on short-term outcomes and negating the long-term 
outcomes such as scarring, which are important to the patient. Scarring is one of the 
patient-related outcomes that may cause functional and cosmetic problems leading to 
impaired psychosocial well-being (Moi et al., 2016; Tredget et al., 2017). Future studies 
should not just address the needs of payers, but also incorporate those outcomes most 
relevant to patients. It is also acknowledged that the focus on a short time horizon, results 
in a failure of studies to capture the full value of an intervention (Kim et al., 2017). 
However, in this analysis, this expected to bias the results against the more effective 
intervention thus making the findings of this study conservative.  
5.4 Conclusion 
This analysis found ACTICOAT to be the most cost-effective silver dressing, followed by 
AQUACEL AG and MEPILEX AG, whereas SSD is the least cost-effective from the perspective 
of the payer. These results were robust in sensitivity analysis. This conclusion supports the 
clinical evidence presented in Section 4.5, which showed greater reductions in LOS in favor 
of ACTICOAT dressing, when compared with other newer silver dressings included in this 
study. Prospective head-to-head research on the costs and outcomes of these newer silver 
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dressings in this patient population are necessary to validate the results of this economic 
evaluation. These studies should also consider the long-term patient outcomes, to acquire 
a comprehensive understanding of the value of these dressings. This study has the 
potential to transform burns management in developed countries, especially in those that 
are implementing value-based reimbursement.  
The next papers will critically review the cost utility analysis of sNPWT in incision 
management to prevent SSCs following a) total hip and knee arthroplasty (THA/TKA) and 
b) cardiothoracic surgery based on data from single-center RCTs.  
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5.5 Cost-effectiveness evidence of single use negative pressure wound 
therapy in preventing surgical site complications (SSC) 
The burden of SSC has been discussed in Section 2.4. A number of techniques are used to 
prevent or reduce the occurrence of SSC including the use of negative pressure wound 
therapy. There are a variety of sNPWT devices and one such is PICO™ (Smith & Nephew, 
Hull, United Kingdom), a canister-free system consisting of a sterile pump and multi-
layered adhesive dressings. PICO has been evaluated by the UK National coverage and 
reimbursement body NICE, and was deemed to be cost neutral at the least and cost saving 
in most of the surgical procedures evaluated.  
Two of the studies described below formed part of the evidence base that was used in the 
decision-making process to grant coverage for PICO by NICE in closed incision 
management. The two cost-effectiveness studies evaluated in this section were conducted 
in two different surgical procedures using clinical evidence from single RCTs, one study in 
patients following hip and knee replacement surgery in the UK (Karlakki et al., 2016) and 
the second study, in patients following cardiothoracic surgery in Poland (Witt-Majchrzak 
et al., 2015). 
 
5.5.1 Study 4: https://onlinelibrary.wiley.com/doi/epdf/10.1111/wrr.12530 
5.5.2 Study 5: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171177/ 
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5.6 Description of Studies 4 and 5 
In both Studies 4 and 5, the economic study type was a cost utility analysis utilising a 
decision tree model designed to capture outcomes following a surgical procedure 
(THA/TKA or cardiothoracic). Both studies used clinical data from single-centre RCTs from 
the payer’s perspective. As in Study 3, a decision tree was considered appropriate due to 
the short timeframe for which the outcomes were evaluated. Furthermore, PICO is used 
prophylactically to prevent the occurrence of SSC, which are measured within 6 weeks of 
the index procedure. Thus, the model did not capture recurring events, otherwise a Markov 
model would have been considered, which is suitable for handling recurring outcomes.  
The outcome of interest was SSC, defined as (length of stay, surgical site infections and 
dehiscence), costs and health-related quality of life. Baseline data without PICO was 
sourced from relevant country specific literature, whereas effectiveness of PICO was taken 
from the individual RCTs. Local national resource use, rather than trial-based data, were 
used in order to enhance the generalisability of the cost-effectiveness results beyond the 
single centres where the RCTs were performed. Both outcomes and costs were not 
discounted because of a shorter time horizon. Sub-group analyses were performed to 
ascertain which groups of patients would benefit most from PICO treatment. One-way 
sensitivity analysis and probabilistic sensitivity analysis was implemented to capture the 
uncertainty around model inputs. 
The results demonstrated that the use of PICO was associated with better clinical outcomes 
and was less costly when compared with standard of care for patients undergoing hip and 
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knee replacement. The estimated cost-saving was £1,132 per patient. Probabilistic 
sensitivity analysis showed that PICO was cost saving in 79% of the 2000 simulations that 
were conducted, suggesting that clinicians and payers can be confident that PICO is indeed 
cost saving. 
Similarly, the results for patients undergoing cardiothoracic surgery demonstrated that 
PICO was associated with better clinical outcomes and lower costs when compared with 
SC. The estimated cost-saving were €586 per patient. Probabilistic sensitivity analysis 
demonstrated that the probability that PICO was cost saving is 100%, further suggesting 
that there is no uncertainty associated with this finding.  
When a series of one-way sensitivity analyses were conducted, such as the effectiveness 
of PICO and its costs, the models remained cost-saving from the payer’s perspective. Sub-
group analysis demonstrated that patients at higher risk of SSC, such as those with higher 
body mass index, diabetes, smoking and American Society of Anesthesiologists (ASA) score 
greater than 3, benefited more from PICO treatment. There were huge savings associated 
with targeting such high-risk patients.  
5.7 Evaluation of Studies 4 and 5 
The two studies suggest that PICO is cost saving from the payer’s perspective compared 
with standard of care when used prophylactically following primary hip and knee surgery 
or cardiothoracic surgery. Both Studies 4 and 5 were subjected to one-way sensitivity 
analysis, as well as probabilistic sensitivity analysis, and the results remained robust, 
suggesting the findings are unlikely to be a result of chance. There are no previous cost-
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effectiveness publications in the use of PICO in these populations. Therefore, these 
findings can serve as reference point with which these can be compared in the future. 
However, another study was published after these two publications, which focused on 
prevention of SSCs following caesarean surgery (Hyldig et al., 2019). The study concluded 
that PICO was a cost-saving intervention in this patient population.  
Study 4 and 5, together with the additional research I did (Nherera et al., 2019a; Nherera 
et al., 2019b), were used by the UK Technology appraisal assessment body NICE, in 
reaching their decision to grant market access for PICO use in the UK NHS 
(https://www.nice.org.uk/guidance/mtg43/chapter/1-Recommendations). PICO has seen 
growth in market share, which among other factors is attributed to the publication of Study 
4 and 5, including the additional research mentioned (Nherera et al., 2019a; Nherera et 
al., 2019b). For the first time, PICO sales have hit the $100 million mark in 2019, and is 
projected to continue growing (See attached confidential E-mail). The use of clinical and 
cost-effective evidence has clearly benefited patients, payers, and manufactures alike. 
Patients are receiving effective therapy, payers are optimising their budgets, and 
manufactures are getting a return on their investment.  
One of the strengths of the two studies is the fact that the comparator used was chosen 
by the clinician, as they often do in daily clinical practice. Having an appropriate 
comparator is key to the external validity and generalisability of the results. Choosing an 
inappropriate comparator may weaken the utility of an analysis, or in the worst-case 
scenario, invalidates the results of a research (Henrickson et al., 2012). 
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One of the main concerns for payers and providers of health services is over-utilisation of 
new devices, especially due to aggressive marketing from manufacturers. These studies 
were designed and conducted in a way that helps payers and providers to target the PICO, 
to those patients who will benefit the most. Sub-group analysis demonstrated that those 
at high risk would derive greater benefit in particular patients with a body mass index >30, 
those with diabetes, and an ASA score >3. This finding will allow a targeted approach to 
adoption, which will optimise efficiency and prevent over-utilisation of the device.  
Both models adopted a payer perspective rather than a societal perspective, yet it is 
understood that the perspective chosen impacts not only on the type of costs included in 
the analysis and also the time horizon of the analysis. Payers are interested in a short time 
horizon, that coincides with their budgetary cycles where possible, because they want to 
realise the savings immediately not sometime in the future (Kim et al., 2017). The societal 
perspective was deemed not necessary, as the studies were done to inform coverage and 
reimbursement decision making, which is adequately answered by the payer’s perspective 
that was adopted. Furthermore, none of the studies considered the budget impact of 
adoption. The payers need to find the money to make the device available to their patients. 
This aspect of affordability was beyond the scope of Studies 4 and 5. 
The RCTs that informed the economic models were conducted at single centers. It is 
acknowledged that each center has its own clinical protocol, which may have confounded 
the clinical outcomes presented, and therefore the estimated savings affecting the 
generalisability of this study. However, the use of a standard care dressing of clinician’s 
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choice, and use of national cost data rather than center-specific costs, may have helped 
with this limitation. Caution is still urged in interpreting the results of the analysis in other 
healthcare systems, since the studies were conducted from the UK and Germany health 
payer perspectives. Other health care systems have different reimbursement systems and 
standard of care differs from one health care system to another, which may affect the 
overall cost-effectiveness conclusions. 
The current studies compared PICO to standard care, however, there are other sNPWT 
devices on the market currently used by healthcare providers. The majority of them do not 
have clinical and economic evidence supporting their use. It is strongly recommended that 
head-to-head studies or ITC be conducted once there is enough evidence gathered for the 
other devices, to assist clinicians and policymakers to choose the most cost-effective 
sNPWT device, thereby increasing efficiency within healthcare systems.  
I have committed myself to conduct an indirect treatment comparison between PICO and 
one its major competitors, Prevena™ Therapy (Acelity, San Antonio Texas, USA). Prevena 
now has accumulated data compared to standard care following cardiac and caesarean 
surgical procedures. This research is already underway, including the economic evaluation, 
and I am expecting to have preliminary results sometime in the second quarter of 2020. 
5.8 Conclusions 
These cost-utility analyses demonstrated that PICO is cost saving compared to standard 
care in preventing SSCs following primary hip and knee replacement, and cardiothoracic 
surgery. The analysis demonstrated improved clinical outcomes and lower overall costs 
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from the UK NHS and Germany payer’s perspective. These studies provided new insights, 
as they were the first cost-effectiveness studies evaluating PICO in these indications. 
Furthermore, these studies contributed to PICO being widely recommended for use in the 
UK NHS. The studies helpfully suggested a targeted adoption of PICO, focusing on high-risk 
patients initially in order to optimise the limited healthcare budgets. Evidence suggests 
some sNPWT have accumulated some evidence, therefore, there is need to conduct direct 
head-to-head or ITC and also a cost-effectiveness study, in order to rank which among the 
different devices optmises the health benefits. As a result of this observation, I have 
embarked on further research assessing both the clinical and cost-effectiveness of PICO 
devices using clinical evidence from ICT. In the future, budget impact models need to be 
considered to ensure payers can afford the recommended devices. 
5.9 Chapter Summary 
This chapter has presented three wound care economic evaluations: one in the use of silver 
dressings in burns and two in the use of PICO in preventing SSCs. The studies on burns 
provided significant new knowledge, which will help providers to prioritise burn treatment 
as the new silver dressings were ranked in order of clinical and cost-effectiveness. 
However, there is need for more head-to-head studies considering long-term patient 
outcomes with standard definitions of some of the outcomes.  
Studies 4 and 5 (Section 5.7) demonstrated that PICO was cost-effective compared with SC 
in managing post-surgical wounds. The studies were able to identify patients that should 
be prioritised for PICO treatment in the event of budgetary constraints. Furthermore, the 
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need for economic analysis based on head-to-head or indirect treatment comparison of 
negative pressure devices was identified, as there are a number of such devices in the 
market now. The two economic evaluations on PICO have already had a positive 
contribution to the policy debate around adoption of PICO in UK NHS, as they were used 
as part of evidence which led to the acceptance of PICO in the NHS through NICE approval 
MTG43 (https://www.nice.org.uk/guidance/mtg43/chapter/1-Recommendations). 
However, both studies did not consider budget impact of these interventions, which was 
beyond the scope of this analysis, but is nonetheless an important consideration if the new 
effective technologies are to be adopted and used in clinical practice. 
The next chapter will present the generation and use of clinical evidence in MSK disorders, 
using the example of patients with intertrochanteric hip fractures. The methodology used 
in both clinical and economic evidence generation are similar to those presented in the 
wound care sections, as policymakers and health care providers are interested in approving 
medical devices that can improve the health of their populations and lower the cost of 
health care. 
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6 Chapter 6: Clinical evidence from musculoskeletal disorders: the 
case of intramedullary (IM) nails in unstable intertrochanteric 
fractures  
6.1 Introduction  
Amongst the many MSK disorders, hip fractures are considered to be a major public health 
problem given their contribution to patient morbidity, mortality, and health care and 
societal costs, as mentioned in Section 2.5. Health care services worldwide are facing 
severe financial pressures, which has created a strong clinical and economic incentive to 
prioritise devices that will optimise patient outcomes. As noted by Papadimitriou et al., 
(2017), there are considerable opportunities to ameliorate the burden of hip fractures, by 
focusing on treatments that will facilitate a rapid and complete recovery.  
Two studies are presented here that help answer questions on the use of IM nails in 
patients with unstable intertrochanteric fractures. Systematic review and meta-analysis 
methods were used in Study 6 to assess the performance of a twin-screw integrated 
cephalomedullary nail (InterTAN) compared with a single-screw cephalomedullary nail 
(Proximal Femoral Nail Antirotation) (PFNA™), (DePuy Synthes, Solothurn, Switzerland). 
Study 7 went a step further and pooled together evidence from single-screw nails (PFNA + 
Gamma3™; (Stryker, Schönkirchen, Germany) and compared this with twin-screw InterTAN 
in the same patient population. In Study 7, I further explored the hypothesis that there 
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could be a class effect between intramedullary devices in patients with unstable 
intertrochanteric hip fractures.  
6.1.1 Study 6: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834859/ 
 
6.2 Description of Study 6 
PFNA and InterTAN are two of the market-leading IM nails used in the management of 
unstable fractures. A number of studies have been conducted directly comparing these 
two devices (Zhang et al., 2013; Seyhan et al., 2015; Yu et al., 2015; Zehir et al., 2015; 
Zhang et al., 2017a; Zhang et al., 2017b). The individual study findings are inconsistent for 
instance results on revisions show no difference between InterTAN and PFNA for studies 
by Zhang et al (2017a) and Zehir et al (2015), while Zhang et al (2017b) shows a significant 
difference in revisions. This makes it harder for surgeons to identify the ideal treatment 
option for their patients or payers to optimise their budgets. Study 6, was therefore 
conceived with aim of addressing this question of inconsistency between individual studies 
reported in literature as well as updating a recently published meta-analysis by Ma et al., 
(2018), by conducting a SLR and pairwise a meta-analysis.  
For the SLR, searches of RCTs and comparative observational studies were carried out from 
the main clinical bibliographic databases mentioned earlier in Section 4.2. The search dates 
were limited to January 2005 to May 2016, because InterTAN was licensed from 2005. The 
study collected three types of outcomes: functional outcomes (Harris Hip Score [HHS]), 
61 
 
post-operative implant-related failures (revisions), and intra-operative procedure 
measures.  
Studies were assessed for quality using the Cochrane risk of bias tool and the GRACE 
checklist for RCT and observational studies, respectively (Higgins et al., 2011; Dreyer et al., 
2014). A meta-analysis was performed using either random or fixed-effects model, and 
summary measures for the meta-analysis were odds ratios (OR) for binary outcomes or 
mean differences (MD) continuous outcomes. The main analysis reported results for the 
combined RCT and observational studies. In sub-group analysis, results were then reported 
separately by study design. 
After applying the inclusion/exclusion criteria, 6 studies (2 RCTs and 4 observational 
studies; 970 patients) were included in the meta-analysis. The analysis demonstrated that 
there was a statistically significant difference (p < 0.05) OR and 95% CI for revisions [0.27; 
95% CI: 0.13 to 0.56], implant-related failures [0.16; 95% CI: 0.09 to 0.27], proportion of 
patients complaining of pain [0.50; 95% CI: 0.34 to 0.74) in favour of InterTAN. There was 
no difference in non-unions and HHS (p > 0.05) and operating times between the two 
devices. The study also showed significant differences in blood loss and fluoroscopy usage 
in favour of PFNA. Sensitivity analysis were conducted considering study design (RCTs and 
observational studies individually), using alternative analytical methods of random or fixed 
effects models. Furthermore, studies which contained mixed populations of stable and 
unstable patients were also removed from the analysis as part of sensitivity analysis. 
Changing these assumptions did not alter our base conclusions that InterTAN was superior 
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compared to PFNA. Furthermore, we removed three studies which had mixed population 
consisting of 25% stable patients (Seyhan et al., 2015; Zhang et al., 2017a; Zhang et al., 
2017b) and the conclusions did not change, suggesting the SLR and meta-analysis findings 
are robust. 
6.2.1 Study 7: https://www.oatext.com/pdf/ROM-3-156.pdf 
 
6.3 Description of Study 7  
One of the limitations of Study 6 in Section 6.2 above was that the scope was too narrow 
and excluded another single-screw nail that had comparative evidence against the twin-
screw nail InterTAN in this population. Study 7 is therefore an update of the previous Study 
6 and another meta-analysis (Ma et al., 2017). Study 7 combined all single-screw nail 
studies of PFNA and Gamma3 and compared them to the twin-screw InterTAN, to 
comprehensively assess the difference in outcomes and test the hypothesis that there 
could be a class effect between twin-screw and single-screw IM nails in patients with 
unstable intertrochanteric fractures.  
The study methods were similar to Study 6, as presented in Section 6.2 above, which 
consisted of an SLR and pairwise meta-analysis of RCTs and observational studies of single-
screw IM nails compared to twin-screw InterTAN. Unlike Study 6, this study considered all 
single-screw IM nails that had comparative evidence against twin screw InterTAN (both 
PFNA and Gamma3 nails). The main analysis, therefore, reported the combined results of 
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single-screw studies together and sensitivity analysis considered the single screws 
individually. 
Following the application of the inclusion and exclusion criteria, 12 studies with 1,661 
patients were included in the meta-analysis: 8 comparing twin-screw InterTAN with PFNA, 
2 additional studies from the previous Study 6, and 4 comparing twin-screw InterTAN with 
Gamma3. The results demonstrated that there were significant differences in device 
performance in favour of twin-screw InterTAN compared with single-screw nails for 
implant-related failures (p < 0.0000), fewer revisions (p < 0.0001), hip and thigh pain (p = 
0.0009), and better function as measured by SF-36 (p = 0.002) and HHS (p = 0.02). 
Procedure outcomes, defined as operating time and fluoroscopy time, significantly 
favoured single-screw nails (p = 0.02 and p = 0.0001, respectively). No differences were 
observed in non-unions (p = 0.28), blood loss (p = 0.35), and other complications (p = 0.94).  
6.4 Evaluation of Studies 6 and 7 
The two studies presented in Sections 6.2 and 6.3 build the case for twin-screw nail 
InterTAN in the management of intertrochanteric fractures. Twin-screw nail InterTAN 
resulted in significantly fewer implant-related failures and revisions, less hip and thigh 
pain, and better function as measured by SF-36 and HHS compared with single-screw nails 
(PFNA and Gamma3). Procedure outcomes were favourable to single-screw IM nails, such 
as operating time, fluoroscopy time, and blood loss, and no differences were observed for 
non-unions.  
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There is one systematic review (Ma et al., 2017) that considered the same question and 
had a different conclusion around revisions and HHS. Study 7 included three additional 
studies (Zhang et al., 2017a; Zhang et al., 2017b; Gavaskar et al., 2018) published after Ma 
et al., (2017), which explains the different conclusions. The findings of this study are thus 
the most up to date, and should be preferred for coverage and reimbursement decision 
making. 
In a sub-group analysis, single-screw IM nails were considered individually, and the results 
showed that the twin-screw InterTAN had better outcomes when compared with PFNA as 
was demonstrated in Study 6. When compared to Gamma3, the only differences were seen 
on quality of life and implant-related failures. This suggests that more studies are needed 
to compare InterTAN with Gamma3, as in the overall analysis there were 8 studies 
comparing InterTAN with PFNA and 4 comparing InterTAN with Gamma3. 
A comprehensive search strategy was implemented in the main clinical databases, which 
ensured all comparative evidence was captured and included in the analysis. This was 
evident, as this study was able to identify one additional study which an earlier analysis by 
Ma et al., (2017) had missed, and 2 new publications. Furthermore, combing both 
observational and RCT evidence ensured that advantages of both study designs were 
optimised in a single analysis. The use of recommended checklist to assess study quality 
ensures that clinicians, patients, and policymakers have confidence in the research 
outputs, a necessary condition for implementation and adoption of the clinical findings. 
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One of the key limitations of Study 7 is the assumption that all single-screw IM nails are 
the same by combining of Gamma3 and PFNA studies in the analysis. This may have 
introduced substantial clinical heterogeneity in the analysis, which may have biased the 
results; the direction of the bias is unknown. However, sensitivity analysis was conducted 
assessing each individual single-screw nail separately. The results of the sensitivity analysis 
demonstrated that InterTAN was superior when compared with PFNA and that more 
evidence was needed for Gamma3, as the only difference was observed in implant-related 
failures and HHS.  
Study 7 has had a positive impact for Smith and Nephew the manufacturer of the twin-
screw InterTAN. The company’s annual report for 2017 states that, “new clinical evidence 
supported increased uptake of our TRIGEN™ INTERTAN™ hip fracture system” and sales in 
the Trauma business increased by 13% from $475 million in 2016 to $495 million in 2017 
(Smith and Nephew, 2017). Furthermore, the availability of good clinical evidence is being 
used to engage with clinicians and payers. For instance, in South Korea InterTAN has been 
granted a 10% increase in price based on the evidence presented in this Chapter and the 
Section 7.3 below.  
6.5 Conclusion 
The studies found that there was a significant difference between twin-screw InterTAN and 
single-screw IM nails (PFNA + Gamma3) with regards to implant-related failure outcomes, 
whereas procedure-related outcomes tend to favour single-screw nails. No difference was 
observed for the outcome of non-union, which is not widely reported in the studies. Future 
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studies should focus on reporting non-unions among other outcomes. Additional studies 
are also needed comparing InterTAN with Gamma3, as there are currently limited data in 
this area.  
6.6 Chapter Summary 
This chapter examined the evidence around the relative effectiveness of IM nails in 
patients with unstable intertrochanteric fractures. The first study (Study 6, Section 6.2) 
compared InterTAN with PFNA alone. It demonstrated that InterTAN was clinically superior 
compared to PFNA, except for procedure outcomes, which favoured PFNA. This is the first 
meta-analysis of its kind contributing to unambiguous understanding of the benefits of 
InterTAN. The study also confirmed what was already known regarding procedure 
outcomes, for instance, the increase in both operating time and blood loss. However, 
experts believe the clinical benefits far outweigh the negatives of procedural benefits. For 
non-unions, there was no difference between the performances of the devices.  
Study 7, Section 6.3 further highlighted the superiority of two screw InterTAN when 
compared with the two most common single-screw IM nails. The study also helped to reject 
the notion that all IM nails are the same, as the twin screw nails was demonstrated to be 
a superior construct compared with single-screw IM nails. As in the Study 6, there were no 
differences on non-unions between the twin-screw and single-screw devices. This is partly 
explained by the fact that out of the 12 studies that were included in the analysis, only 4 
reported on non-unions. Future studies should be encouraged to report on this outcome. 
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Also, more studies on Gamma3 and InterTAN are needed, as currently only 4 of the 12 
included studies compared the two devices head to head.  
Demonstrating clinical effectiveness is one step towards achieving coverage and 
reimbursement of medical devices in today’s resource-constrained environments. 
Currently, there are no published cost-effectiveness studies comparing the different IM 
nails in patients with unstable fractures. Cost-effectiveness arguments have become so 
important for coverage and reimbursement decision making, as healthcare systems are 
faced with falling budgets. Therefore, the next chapter will look at the cost-effectiveness 
of IM nails InterTAN, Gamma3, and PFNA in patients with intertrochanteric fractures using 
the clinical data from the meta-analysis presented in Section 6.3. 
  
68 
 
7 Chapter 7: Cost-effectiveness evidence of Intramedullary (IM) 
nails in patients with unstable intertrochanteric fractures. 
7.1 Introduction 
The previous chapter focused on the clinical effectiveness evidence of IM nails, in 
particular the three commonly used IM nails InterTAN, PFNA, and Gamma3. The clinical 
evidence suggested that the twin-screw nail InterTAN was clinically superior when 
compared with single-screw IM nails in patients with unstable intertrochanteric fractures. 
However, the cost-effectiveness of these devices was not examined, to assess if the added 
clinical benefit represents value for money to payers. This chapter focuses on the economic 
evaluation of IM nails using the clinical findings of the previous Study 7, Section 6.3, as 
inputs of the economic analysis. The analysis is conducted from the perspective of US payer 
with a view to assist clinicians with device selection and payers with coverage and 
reimbursement decisions. 
7.1.1 Study 8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117956/ 
 
7.2 Description of Study 8 
A decision analytic model using a decision tree was developed in Microsoft Excel to 
estimate the expected outcomes and mean costs of patients with unstable 
intertrochanteric hip fractures treated with either twin-screw InterTAN or single-screw 
nails (PFNA + Gamma3) from the US payer perspective. The choice of the modelling 
69 
 
technique was informed by previously published studies in this area and the clinical studies 
from which the data was sourced. The model timeframe was 12 months and therefore no 
discounting was done for both costs and benefits. Following surgery, patients would either 
experience no complications or they had complications (non-union, implant-related 
failure). The complication would result in revision surgery, including the possibility of 
death. Baseline model values were taken from the literature and the meta-analysis, 
including health-related quality of life inputs. The analysis also ranked the IM devices in 
order of cost-effectiveness. One-way and probabilistic sensitivity analysis were conducted 
to assess the impact of model inputs uncertainty on the results of the analysis. 
The analysis demonstrated that twin-screw InterTAN was associated with improved clinical 
outcomes and lower costs overall when compared with single-screw IM nails. In such 
instances, when an intervention results in improved clinical outcomes and less overall 
treatment costs, it said to be dominant strategy or a cost saving intervention. The 
estimated savings was $2,700 per patient in the base case analysis. Sub-group analysis 
considering each individual single-screw IM nail demonstrated that twin-screw InterTAN 
saved $3,280 per patient compared with PFNA and $1,652 per patient compared with 
Gamma3. The results remained cost saving from the US payer’s perspective, when model 
inputs such as the effectiveness of the devices on revisions, implant-related failures, and 
cost of implants were varied in one-way sensitivity analysis. Probabilistic sensitivity 
analysis confirmed the findings of one-way sensitivity analysis suggesting that these results 
are robust. Furthermore, the study also considered the analysis from a hospital perspective 
in sensitivity analysis and concluded that twin-screw InterTAN remained cost saving. The 
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estimated savings were calculated to be $414 per patient, when compared with single-
screw IM nails.  
7.3 Evaluation of the study 
The cost-effectiveness of IM nails compared with sliding hip screws in patients with 
unstable fractures was established in a study by Swart et al., (2014) without distinguishing 
which of the IM nails should be preferred first. This study represents the first economic 
evaluation that has compared different IM nail fixation devices in patients with unstable 
fractures, in order to assist clinicians in selecting amongst the commonly used IM nails. 
The study concluded that the twin-screw nail construct InterTAN is cost-saving when 
compared with the single-screw IM nail constructs. Furthermore, the analysis was also able 
to show that among the single-screw IM nails, Gamma3 is the most cost-effective when 
compared with PFNA. The ranking of devices is useful to payers and clinicians, as this assist 
them to prioritise the use of IM nails especially in resource-constrained environments. 
In sensitivity analysis, the study also considered a different perspective, that of the 
hospital, and still concluded that the twin-screw nail construct InterTAN is cost-saving 
when compared with the single-screw IM nail constructs. This is an important 
consideration especially in privately funded healthcare systems where hospitals and 
decision makers want to optimise profitability. In such instances, hospitals may be 
interested in knowing whether particular devices will generate them profit before they 
make purchasing decisions. Equally important is the fact that a hospital with good surgical 
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outcomes is able to attract more patients, thereby boosting patient volumes and 
profitability.  
This research has contributed to the coverage and reimbursement of the InterTAN in South 
Korea, where the device managed to achieve a 10% increase in price based on this 
evidence. InterTAN as a brand has grown globally by 8.6% between 2014 and 2019 (See 
attached confidential e-mails). Smith and Nephew, the manufacturer of the twin-screw 
InterTAN, mention in their annual report from 2017 and 2018 that their Trauma portfolio 
has seen an increase in sales, a key driver for which they attributed to the good evidence 
presented in Study 8. This evidence is thus benefiting patients and clinicians who see 
improved outcomes, payers who are getting the most out of their budgets, and 
manufacturer who are seeing increased profitability.  
As with all modelling exercises, not all possible outcomes were captured. For example, this 
analysis did not explicitly model the progression of patients to total hip arthroplasty (THA). 
In reality, it is possible that patients who need a reoperation to treat a failed internal 
fixation may end up with a conversion to a THA within the first year. This information on 
the conversion rates to THA in patients treated with IM nails is not well characterised in 
the literature. Furthermore, the modelling framework of using a decision tree would have 
made it difficult to incorporate recurrent events such as re-revisions and the possibility of 
THA. In such a situation where there are recurring events that occur over time, a Markov 
modelling framework would have been appropriate. Therefore, one of the key implications 
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of this study is to encourage future researchers to collect information on progression of 
patients to THA and then update the model once such information becomes available.  
This study was carried out from the perspective of the US healthcare payer’s system and 
used average Medicare reimbursement as a proxy for the hospital costs. As in most 
economic evaluations, caution should be taken when interpreting these results in other 
healthcare systems and encourage the use of local costs to test the robustness of this 
analysis on individual healthcare systems.  
The study also focused on short time horizon of one year which undoubtedly addresses the 
payer’s needs in the time frame selected. However, IM nails are known to have longer 
survival or lasts for far longer periods beyond the one year considered in this study. By 
limiting the analysis to one year, there is an implicit assumption that incremental costs and 
health benefits are zero beyond the one year modelled, which under-estimates the true 
costs and benefits of the interventions (Kim et al., 2017). This however, is expected to bias 
the results against the more effective two nail fixation than the single nail and therefore 
is not expected to alter the conclusions of Study 8 which was found to have less implant 
related failures and costs less overall. 
7.4 Conclusion 
This study demonstrated that twin-screw InterTAN offers better clinical outcomes at lower 
overall costs when compared with single-screw nails in patients with unstable fractures. 
These findings remained robust when different assumptions were tested in sensitivity 
analysis, suggesting they are unlikely to be a chance finding. Given that currently there is 
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no guidance as to the choice of IM nailing system, this study can have huge implications 
and encourage clinicians and policymakers to adopt the most cost-effective technology. 
This research is having a demonstrable impact in other health care markets, such as South 
Korea. Smith and Nephew have seen increases in sales reported in their annual report. This 
is proof that when a technology is backed by good clinical and cost-effectiveness evidence, 
it will be adopted for the benefit of patients, payers, and manufacturers alike. Long-term 
follow-up studies are needed to ascertain the benefits beyond the 12 months reported in 
the clinical studies. Data on the possibility of conversion to THA following device failures 
are also needed to fully quantify the benefits of the different nailing systems. 
7.5 Chapter summary 
This chapter presented an economic evaluation of IM nails used in patients with unstable 
intertrochanteric fractures and supports the use of twin-screw InterTAN nail compared 
with single-screw IM nails (PFNA and Gamma3). The existing knowledge was around cost-
effectiveness of IM when compared with sliding screws, and none looked at IM against 
each other. Therefore, this is the first study that has compared IM nails against each other 
and provided new insights in this patient population regarding the performance of the 
commonly used IM nails.  
Studies with longer time horizon are needed to confirm if the benefits persist beyond the 
reported one year, and also include outcomes of possible conversion to THA for patients 
whose implants fail at one year. This will further assist clinicians and policy makers in 
choosing the technology that optimise the clinical benefits for their patients given the 
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limited budgets with which they are working. The current study has already had a positive 
impact with regards to reimbursement. For instance, twin-screw InterTAN has been 
granted a 10% increase in price in South Korea by their health watchdog Health Insurance 
Review and Assessment Service, over and above other IM nails because of the clinical and 
cost evidence presented in Study 8 [See attached confidential e-mail].  
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8 Chapter 8: Summary, Conclusions and Recommendations 
8.1 Thesis Summary 
Chapter 1 highlighted the increasing demand by decision makers for more robust evidence 
demonstrating the value of new medical devices in order to optimise patient health. This 
is particularly important given the burden of wounds and MSK disorders is increasing due 
in tandem with the rise in chronic diseases and life expectancy, among other factors. As a 
result of this increased burden, there are huge pressures on healthcare budgets and the 
need to ensure efficient allocation of the limited healthcare resources. One such method 
is using the best available clinical evidence and incorporating economic evaluations in the 
coverage and reimbursement decision-making process.  
The overall aim of the thesis was to evaluate the clinical and health economic evidence 
used to inform coverage and reimbursement of medical devices using examples from 
wound care and MSK health. The thesis demonstrated that having good clinical evidence, 
and incorporating health economic evidence is a necessary but not sufficient condition for 
ensuring efficient allocation of limited resources. Study 1, presented in 4.5 has resulted in 
the update of the EBA clinical guideline in 2017, whereas Studies 2 and 3 in Sections 4.6 
and 5.3 are yet to have a demonstrable impact on guidelines. Studies 4 and 5 in Section 
5.6 and Studies 6,7 and 8, in Section 6.4 and 7.3 have demonstrated that using good clinical 
and economic evidence can result in positive coverage decisions benefiting manufacturers, 
patients, and payers.  
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The thesis presented and critically appraised 8 publications: 5 studies published by the 
researcher focused on wound care (burn and surgical site wounds) and 3 in MSK disorders 
(unstable intertrochanteric fractures). The thesis has shown how the different publications 
have formed a coherent body of evidence for wound care and MSK disorders, and 
demonstrate that good clinical and economic evidence can be a vehicle for optimal 
coverage and reimbursement decision for medical devices, which will benefit patients, 
payers, and manufacturers alike.  
8.2 Contribution to Knowledge 
Study 1, in Section 4.3, and Study 2 in Section 4.6, examined the relative effectiveness of 
silver dressings in patients with superficial and partial-thickness burns. Silver dressings are 
already known to be effective in preventing infections compared with standard care. 
However, what was unknown was which amongst the silver dressings was the most 
clinically and cost-effective. Both Studies 1 and 2 demonstrated that ACTICOAT was the 
most clinically effective silver dressing amongst the newer silver dressings. This clinical 
evidence was then used to inform the cost-effectiveness study, which confirmed that not 
only is ACTICOAT clinically effective, is also cost-saving.  
As was identified in Section 4.1., there is currently no guidance as to which dressing should 
be preferred due to lack of evidence on newer antimicrobials (WUWHS, 2016; EBA, 2017). 
Study 2, Section 4.6 in particular has contributed to the debate of which among the newer 
silver dressings is clinically effective, by pointing clinicians and policymakers to the ranking 
of different dressings outlined in this thesis. The current EBA (2017) guideline now 
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acknowledges that ACTICOAT results in reduced length of hospital stay, citing evidence 
presented in Study 1 Section 4.3, which was published in 2016. It is anticipated that the 
next round of the EBA guideline update due in 2020 will incorporate evidence from the ICT 
and cost-effectiveness studies that provided a ranking of the silver dressing in order of 
clinical and cost-effectiveness. Smith and Nephew has seen its silver dressing market share 
grow as a result of the convincing evidence presented in this thesis. The sales and 
marketing have updated their claims based on the results of the meta-analysis to include 
claims around reduction in LOS, reduction incidence of surgical procedures and pain 
compared to standard of care.  
Chapter 4 also demonstrated that performing an appropriate Health Technology 
Assessment does have a significant benefit for the patients, payers, and the 
manufacturers. SSCs are a huge drain on the health care budgets and using modern 
advanced wound care devices can help lessen their incidence. The cost-effectiveness of 
PICO following hip and knee or cardiothoracic surgery contributed new understanding on 
the performance of this device in these patient populations. Studies 4 and 5 in Section 5.6, 
have led to a positive recommendation for the widespread adoption of PICO 
(https://www.nice.org.uk/guidance/mtg43/chapter/1-Recommendations) in the UK NHS, 
which is an important practical contribution. Patients now have wider access to an 
effective intervention and the payers are optimising their budgets.  
Equally, the systematic review and meta-analysis of IM nails presented in Chapter 6, 
updated an existing meta-analysis by Ma et al., (2017) (Study 7, Section 6.3). No 
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controversy exists regards the superiority of the twin-screw nailing system around implant 
failures when compared with single-screw nailing system, and this analysis further 
confirmed this assertion. However, the study added new understanding around pain, 
health-related quality of life, and revision rates, which were all shown to favour the twin-
screw nailing system. The hypothesis that all IM nails (twin-screw or single screws) are the 
same was also dismissed by this study, as the twin-screw nailing system was shown to be 
superior compared with the single-screw nailing system.  
Chapter 7 summarised the cost-effectiveness of the IM nails utilizing data from the clinical 
meta-analysis presented in Chapter 6, Section 6.3. This is the first published economic 
analysis that considered the twin-screw InterTAN and concluded that it was cost-effective. 
Furthermore, the study provided additional information that among the single-screw nails, 
Gamma3 is the preferred choice compared with PFNA according the evidence presented in 
this thesis. 
8.3 Implications of the Thesis 
The research summary findings have been presented in the preceding Section 8.1. In 
Chapters 4 and Chapter 5, the thesis described the clinical effectiveness and cost-
effectiveness evidence in burn wound care, respectively. The thesis concluded that 
ACTICOAT is clinically superior and the most cost-effective dressing among the newer silver 
dressings, as evidenced by fewer infections and reduced LOS. It is important to 
acknowledge that the evidence was not a direct comparison and some of the outcomes are 
not defined in a standard way. However, as stated in Section 4.1. there is currently no 
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guidance on which silver dressing should be preferred in this patient population, due to 
lack of evidence. The findings of this research can be used by clinicians, policy makers, and 
payers to give guidance regarding the most clinically and cost-effective dressing. This will 
be a great starting point while further head-to-head research between the main silver 
dressings is conducted.  
One of the significant findings of this thesis is in Section 5.6, where a pertinent question 
was addressed regarding the use of negative pressure wound therapy in closed surgical 
incisions to prevent complications following surgery. Negative pressure is certainly an 
innovative advanced wound dressing. As with any new technology, it needs to have proven 
evidence before it can be widely used. Studies 4 and 5, in Section 5.6 used evidence from 
published RCTs and reported the cost-effectiveness results where PICO was found to be 
cost-saving in patients following hip/knee and cardiothoracic surgery. The studies further 
found that the dressing was more effective in patients at high risk of SSC. This has 
significant implications as the research not only proved that negative pressure wound 
therapy is cost-effective and therefore should be recommended for use, but also that the 
dressing should be targeted at those patients with increased risk of contracting SSC/I. This 
is important to payers as it potentially avoids over-use of new technologies in times when 
budgets are tight. The studies have already had a positive impact as they were used as part 
of the decision that led to PICO being recommended for widespread use in the UK NHS 
MTG43 (https://www.nice.org.uk/guidance/mtg43/chapter/1-Recommendations). The 
manufacturer is also benefiting from the wider use of their technology, thereby optimising 
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their return on investment. As of November 2019, the manufacturer of PICO has seen PICO 
sales hit the $100 million mark for the first time (See attached confidential e-mail). 
This thesis also found evidence to support the use of twin-screw nailing system over single-
screw nailing system in patients with unstable intertrochanteric fractures. This is 
significant new evidence which should be used by policymakers and clinicians to update 
their guidance with regard to device selection in this patient population. Furthermore, 
among single-screw IM nails, Gamma3 should be preferred over PFNA on cost-
effectiveness grounds. The studies on MSK disorders have had a positive policy impact, 
resulting in an increase in a 10% price increase of InterTAN device for the manufacturer in 
South Korea as the healthcare insurer was convinced by the clinical and cost-effectiveness 
evidence presented in this thesis. InterTAN as a brand has grown globally by 8.6% between 
2014 and 2019 according to the manufacturer (See attached Confidential E-mails in 
appendix). 
Furthermore, medical devices do not always have the abundance of evidence as in 
pharmaceutical research. This thesis has shown that when the evidence is available, the 
same methodological rigor should be applied in assessing the device usefulness in clinical 
practice. In this thesis, good evidence underpinned the conclusions for wound care and 
MSK disorders where SLRs and meta-analyses were conducted and informed the 
conclusions. The idea of pulling together RCTs and observational studies has greater utility 
in medical devices where conducting trials is difficult, in particular due to obstacles in 
blinding and smaller numbers of study participants. It is therefore imperative for 
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policymakers to accept the utility of using all available evidence. The adoption of this 
methodology in medical devices, especially wound care and MSK disorders, is going to 
ensure that no clinical evidence is overlooked and that patients have access to clinically 
and cost-effective interventions.  
8.4 Limitations of the Thesis 
As discussed above in Section 8.2, this research has addressed gaps that existed in 
literature and at the same time contributes to new knowledge in the field. However, there 
are limitations of the thesis that need to be acknowledged. Regarding cost-effectiveness 
analyses, the economic models adopted the healthcare payer’s perspective. This approach 
favours publicly funded healthcare systems where the tax payers are responsible for 
paying for health provision. In the cases where a mix of both public and private payers, as 
in the United States and other countries where co-payments exists, productivity costs and 
out-of-pocket expenses for the patient, family, and friends have not been accounted for, 
which may underestimate the total costs of associated with a medical device. 
Consequently, there is a need to formally assess the impact of modelling from a societal 
perspective. The societal perspective considers all costs, including productivity loss, and 
patient and care givers costs. However, the analyses presented in Sections 5.3, 5.6, and 
7.3 can be considered conservative and therefore likely to underestimate the true cost 
benefits, as payer perspective does not include all relevant costs and benefits in their 
analyses. Furthermore, the economic evaluation studies focused on short-term time 
horizons. Limiting studies to shorter time horizons may address the needs of payers, 
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however, there is a danger of not adequately capturing the full costs and benefits of 
interventions, which tend to be underestimated over a shorter time horizon. Focusing on 
short-time horizon usually biases the results against the more effective interventions. In 
this thesis this is unlikely to alter the conclusions since the more effective interventions 
have been found to be cost-saving even in the short-term.  
This thesis answered questions on clinical and cost-effectiveness with important 
implications around value for money. However, they are not the only important questions 
necessary for full implementation of research recommendations. Value for money does 
not address the affordability question, which is answered by a different type of research, 
the budget impact model. The thesis did not consider budget impact of the interventions, 
which is key in terms of product adoption and patient access to medical devices as this was 
outside the scope of the thesis. There is a lack of congruence between cost-effectiveness 
analysis and budget impact analysis as payers may refuse to pay for recommended 
interventions due to affordability issues.  
Although ITC methods are accepted and well developed, it is always preferable to have 
direct comparative evidence. This thesis demonstrated the lack of such direct evidence in 
the use of silver dressings despite the dressings having been used for more than 2 decades. 
Also, the clinical studies assessed in this thesis for both wound care and MSK disorders had 
short-term follow-up data. In burn injury there are outcomes important to the patient, 
such as scarring, which are not routinely collected.  
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8.5 Recommendations for Further Research 
The thesis presented evidence of clinical and cost-effectiveness for wound care and MSK 
disorders, with focus on burn injury, infection control, and unstable intertrochanteric 
fractures, respectively. The findings and issues raised in this thesis indicate several possible 
avenues for future research that can enhance our understanding of evidence around these 
medical devices in the respective populations.  
For the burn wound care studies, the clinical evidence comprised both RCTs and 
observational studies compared with SSD. There was no direct head-to-head evidence for 
the newer silver dressings and a lack of long-term outcomes such as scarring and other 
cosmesis outcomes, including lack of standard definitions of some outcomes such as LOS. 
Head-to-head studies comparing the new silver dressing in patients with superficial and 
partial-thickness burns should be conducted collecting long-term outcomes, such as 
scarring. These studies are necessary to validate the results of the indirect treatment 
comparison presented in this thesis Section 4.6 and ensure the treatment guidelines are 
updated with confidence. Furthermore, as pointed out earlier in Section 4.8, using 
standardised outcomes ensures that homogeneous outcomes are collected. 
Regarding the prevention of surgical complications, head-to-head studies comparing the 
negative pressure wound devices either directly or via indirect treatment comparison 
methods should be conducted. I have already started the ITC research of PICO compared 
with Prevena in patients following closed incision surgery to assess both the clinical and 
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cost-effectiveness of the two devices. The research is expected to guide payers and 
clinicians to choose the device that will optimise their patient outcomes and budgets.  
For the MSK disorder studies, only 4 out 12 studies that were identified and included in 
the clinical meta-analysis reported on the outcome of non-unions and none reported on 
conversions to THA following revision surgery of unstable fractures. Currently, the 
evidence from this thesis suggests that there is no difference between the performances 
of all IM nails on the non-union outcome. It is not clear if this is genuinely the case or it is 
a result of lack of reporting. It is therefore recommended that future studies should collect 
this (non-union) outcome to enhance our understanding, and further give guidance to 
clinicians and payers of health care. As identified in Chapter 6, there are also few studies 
comparing twin-screw InterTAN with Gamma3 in general. Additional studies comparing 
these two devices in this population are also recommended. 
Economic evaluations attempt to provide information about the most economically 
efficient ways to utilise or allocate available health care resources, and these studies do 
not address the question of affordability. On the other hand, a budget impact analysis 
estimates the financial and organisational consequences of adopting a new health care 
technology without directly taking health consequences into account. Regulatory bodies 
are concerned with value for money and safety of medical technologies, while 
commissioners/insurers or hospitals have to find the money from their budgets to pay for 
recommended interventions. This thesis did not present budget impact analysis of the 
various technologies assessed, which is a worthwhile direction for future research. Future 
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studies considering affordability are therefore recommended to help guide commissioners 
or payers. This will ensure widespread adoption and patient’s access to the medical 
technologies.  
The economic models presented in this thesis used a decision tree modelling technique. 
The advantage of using a decision tree is that they are easy to follow and laid out in a very 
logical and linear fashion. However, decision trees are not suitable in situations where 
there are recurring events and where the relevant time horizon is longer. This was certainly 
the case for the MSK model for intertrochanteric fractures that long-term outcomes could 
have been handled better by a different modelling approach, specifically a Markov 
modelling approach. Markov models are ideal for modelling clinical problems that involve 
risk over time, or when the timing of events is important. Future economic studies should 
consider using the Markov modelling approach especially as they seek to include loner-
term outcomes such as conversion to THA following a failed revision surgery.  
8.6 Conclusions 
In conclusion, the research presented in this thesis has demonstrated that when there is 
good clinical and economic evidence, this can hypothetically result in efficient allocation 
of scarce healthcare resources. The thesis used examples from wound care, where 
ACTICOAT was demonstrated to be clinically and cost-effective in superficial and partial-
thickness burns. Further evidence was presented proving the cost-effectiveness of PICO in 
preventing SSCs. The use of the PICO evidence is a practical example of how clinical and 
economic evidence can inform coverage and reimbursement decisions as illustrated by the 
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decision of NICE in the UK to recommend its use in the NHS. Using examples from MSK 
disorders, this thesis was able to show that the twin-screw InterTAN was the best IM nail 
compared with the single-screw IM nails. The studies on IM nails presented in this thesis 
have resulted in InterTAN price being increased by 10% as payers in South Korea 
acknowledged the value that the device brings to the patient and payers, and 8.6% growth 
in sales of InterTAN between 2014 and 2019.  
The thesis was also able to show that similar evidence types and assessment methods are 
needed for both wound and MSK disorders. However, there were limitations and evidence 
gaps that were identified in the thesis. Necessary future research recommendations have 
been made, which will no doubt increase the understanding of the medical devices 
presented in this thesis and further update current and future guidance. More importantly, 
to ensure widespread adoption and hence access of these devices, budget impact models 
are also needed, and I have challenged myself to contribute to this further research.   
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